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Summary 
Typically, when a beam passes through an immobilisation device, the dosimetric 
effects of that device are ignored or a blanket transmission factor is applied to 
correct the dose calculation.  When the immobilisation device is: 
• not of uniform density; 
• not of uniform thickness or material; or  
• not effectively radio-translucent;  
this can lead to large inaccuracies in the dose calculation. By including the 
physical characteristics of the immobilisation device in the dose calculation by 
the treatment planning system, a more accurate dose distribution may be 
obtained.  However, limitations of some dose calculation algorithms can result in 
errors beyond low density inhomogeneities, such as those created by 
immobilisation devices. Previous studies have shown that algorithms utilising the 
equivalent tissue air ratio inhomogeneity correction method overestimate the 
dose within and immediately beyond low density inhomogeneities.  This is 
primarily due to the assumption that there is electronic equilibrium at all points in 
the dose calculation and the inability of the algorithm to account for changes in 
electron transport caused by inhomogeneities. 
 
Aim 1 
The first aim of this project was to confirm if the Eclipse™ pencil beam 
convolution dose calculation algorithm (when utilising the equivalent tissue air 
ratio inhomogeneity correction) can calculate the dose distribution and monitor 
units to within acceptable clinical tolerances when the treatment fields pass 
though a physically complex and/or low density immobilisation device which is 
included in the dose calculation. 
 
To investigate this aim, treatments were planned using the Eclipse™ treatment 
planning system with a 6 MV photon beam passing through four different 
immobilisation devices (a MEDTEC Contoura™ belly board, a Sinmed 
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Posiboard™-2 breast board, a VacFix® vacuum bag and a MEDTEC Type-S™ 
head extension). The dose distribution and monitor units for the plans were 
calculated with and without the immobilisation device included in the dose 
calculation.  For each device, a simple case using a solid water slab phantom 
and a complex case using an anthropomorphic phantom were studied.  The 
plans were delivered and the dose measured using an ionisation chamber for the 
simple case and thermoluminescent dosimeters for the complex case.   
 
For the simple case, the maximum difference between the measured and 
calculated dose was -8.4% and -1.6% when the immobilisation device was 
omitted from and included in the dose calculation respectively. For the complex 
case, the maximum difference between the measured and calculated doses was 
-7.7% and -2.5% when the immobilisation device was omitted from and included 
in the dose calculation respectively.  For all cases when the immobilisation 
device was included in the dose calculation, the results were within an 
acceptable clinical tolerance level of 2.5%. 
 
Aim 2 
As large air gaps are sometimes created by the use of immobilisation devices, 
the second aim was to determine the magnitude of any errors in the Eclipse™ 
dose calculation for points located beyond large air gaps. 
 
To investigate the second aim, 6 MV photon beam depth dose data was 
measured beyond various thickness of air gap (1, 3, 5, 8, 10, 12.5 and 15 cm) 
simulated by supporting water equivalent slabs (0.2, 0.5, 1, 2, 3 and 4 cm 
thickness) above a water phantom.  A parallel plate ionisation chamber, 
immersed in water beyond the air gap, was used for these measurements. The 
results were then compared to the results predicted by Eclipse™.   
 
The results indicate that for a given thickness of material before the air gap, as 
the air gap thickness increases, the dose at the distal surface of the air gap 
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decreases.  The depth of dose maximum in the material beyond the air gap also 
increases as the air gap thickness increases.  For a given air gap thickness, as 
the thickness of material placed before the air gap increases, the depth at which 
the maximum dose occurs, shifts towards the surface. Eclipse™ does not predict 
the reduction in dose beyond the air gap for any air gap thickness or the 
corresponding shift in the depth of dose maximum. 
 
As the thickness of material before the air gap increases, the reduction in dose 
beyond the air gap continues beyond the re-establishment of electronic 
equilibrium.  In the case of 2 cm thick water equivalent material placed before a 
15 cm air gap, Eclipse™ over-predicts the dose by 34% at the surface of the 
water phantom and by 3%, 3% and 2% at depths of 5, 10 and 15 cm 
respectively.  A scatter analysis found that the reduction in dose beyond the air 
gap is due to a reduction in scattered radiation reaching the measurement point.  
Eclipse™  does not predict this as it does not account for situations of electronic 
disequilibrium (which occur due to the presence of an air gap) or changes in 
electron transport caused by inhomogeneities. It is also due to limitations in the 
equivalent tissue air ratio inhomogeneity correction method when accounting for 
scattered photons. 
 
The current study has shown that including the immobilisation device in the dose 
calculation when the treatment field passes through the device, improves the 
accuracy of the dose calculation to within clinical tolerance levels.  However, 
when large air gaps are created by an immobilisation device, significant errors 
can still result, particularly in the region immediately beyond the air gap.  The air 
gap investigation has extended the range of results obtained from previous 
studies from a maximum air gap thickness of 5 cm to 15 cm and from a 
maximum depth beyond the air gap of 4 cm to 15 cm.  The data obtained in this 
study may be used to apply corrections to dose calculations by Eclipse™ when 
an air gap is present for a broad range of clinical situations. 
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1 Introduction 
 
The aim of radiotherapy is to deliver a precise dose of radiation to a well defined 
target volume with the least possible damage caused to surrounding healthy 
tissues.  The process of radiation therapy using a linear accelerator (LINAC) 
involves many steps prior to treatment, including treatment simulation and 
treatment planning. Treatment simulation involves obtaining computed 
tomography (CT) images of the patient set up in the treatment position for use in 
the treatment planning stage. Treatment planning is conducted using software 
referred to as a treatment planning system (TPS).  It involves defining the target 
volume, selecting the optimum radiation beam angles and field sizes, calculating 
the dose distribution and determining the number of monitor units required to 
deliver the dose.  (A definition of monitor units and how they are calibrated can 
be found in Section 2.1).  The patient’s treatment typically occurs daily over a 
number of weeks (Van Dyk 1999).  
 
The International Commission on Radiation Units and Measurements (ICRU) 
recommends that the absorbed dose to the target volume should be delivered to 
an accuracy of 5% or better (ICRU Report 24 1976). This means that the 
accuracy for each of the plan and treat steps must be better than 2.5% (Van Dyk 
1999).   
 
Immobilisation devices are often used to aid patient set up and limit patient 
motion. They assist in maintaining the accuracy required throughout treatment 
planning and delivery (Van Dyk 1999, Podgorsak 2003, Van Dyk 2003, Khan 
2007).  Low density materials, such as foam or carbon fibre/foam composites, 
are often used to create immobilisation devices with the aim of being radio-
translucent. However, sometimes higher density materials such as solid carbon 
fibre or plastic are required for strength and rigidity or to create a hinge or pivot 
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point to allow the set up to be adjusted or to fix the immobilisation device to the 
treatment couch. 
 
Typically when a beam passes through an immobilisation device, the dosimetric 
effects of this device are ignored or a blanket transmission factor is applied to the 
dose calculation.  When the immobilisation device is not of uniform density or 
thickness or not effectively radio-translucent, this can lead to large inaccuracies 
in the dose calculation.  By including the physical characteristics of the 
immobilisation device in the dose calculation conducted by the TPS, a more 
accurate dose distribution may be obtained. In the Eclipse™ TPS (Varian Medical 
Systems, Palo Alto, CA, USA), this is achieved by including the immobilisation 
device in the body structure defined during the treatment planning process.  
 
Previous studies have shown that algorithms utilising the equivalent tissue air 
ratio (ETAR) inhomogeneity correction method overestimate the dose within and 
immediately beyond low density inhomogeneities.  This is primarily due to the 
assumption that there is electronic equilibrium at all points in the dose calculation 
and the inability of the algorithm to account for changes in electron transport with 
inhomogeneities. The low density inhomogeneities investigated were typically 
representative of those within the patient such as lung (Mackie et al 1985, 
Metcalfe et al 1993, du Plessis et al 2001, Carrasco et al 2004) or small air 
cavities (Wong et al 1992, Wong et al 1996, Shahine et al 1999, du Plessis et al 
2001).   
 
The only study found to have investigated the inclusion of an immobilisation 
device in the dose calculation was by Munjal et al (2006). In this study the dose 
in an Intensity Modulated Radiation Therapy (IMRT) phantom (a device for 
simulating the in vivo interaction of radiation with tissue (Burr et al 1991)) was 
investigated with a field passing through a PMMA (Polymethylmethacrylate) base 
plate supported approximately 8 cm above the phantom. They found that the 
PLATO-SUNRISE TPS, which utilises the ETAR method of inhomogeneity 
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correction, calculated the dose to within 1.5% at the centre of the phantom.  No 
studies investigating the ability of a TPS to calculate the dose through other 
immobilisation devices, such as non-uniform or low density devices were found in 
a literature search.  
 
In practice, large air gaps are sometimes created by immobilisation devices 
which support the patient above the treatment couch.  This problem is common 
when using tilted breast boards, head rests or knee supports.  For example, 
when a posterior field passes through the breast board (see Figure 3.6 (page 
68)), the beam may first pass through the treatment couch and/or the base of the 
breast board, a large air gap then the tilted back support region of the board 
before entering the patient. 
 
When a head rest or knee support is used, fields which pass through the 
treatment couch may also pass through an air gap between the couch and the 
patient.  Examples of a patient treatment for each of these cases are illustrated in 
Figure 4.1 (page 96).  No studies were found in the literature that investigated the 
accuracy of a TPS to calculate the dose distribution behind large air gaps 
(greater than 5 cm) such as those created by immobilisation devices. 
 
Aim 1 
The first aim of this project was to confirm if the Eclipse™ pencil beam 
convolution (PBC) dose calculation algorithm, when utilising the ETAR 
inhomogeneity correction, can calculate the dose distribution and monitor units to 
within an acceptable clinical tolerance of 2.5% when the treatment fields pass 
though a physically complex and/or low density immobilisation device which is 
included in the dose calculation. 
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Aim 2 
The second aim of this project was to determine the magnitude of any errors in 
the Eclipse™ dose calculation for points located beyond large air gaps.  
 
1.1 Thesis Structure 
 
Chapter two discusses the process of radiation therapy and the accuracy 
achievable throughout the process. The Eclipse™ TPS and the aspects of: 
• the dose calculation algorithm (such as the inhomogeneity correction 
method used in this project) and; 
• the use of contoured structures and transmission factors in the dose 
calculation process; 
are described. 
 
In addition, the previously published work relating to the dosimetric effects of 
objects outside the patient is reviewed.  The accuracy of dose calculations 
beyond low density inhomogeneities and air cavities is also reviewed. 
 
Chapter three describes the materials and methods for the simulation and 
delivery of simple and complex patient treatments utilising the following four 
immobilisation devices: 
• MEDTEC Contoura™ belly board; 
• Sinmed Posiboard™-2 breast board; 
• VacFix® vacuum bag and; 
• MEDTEC Type-S™ head extension). 
 
A discussion of the results obtained is also included. 
 
To create a simple case, treatment plans were created for slabs of water 
equivalent material simulating a unit density patient with an immobilisation device 
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placed above the slabs. A treatment field passed through the immobilisation 
device and the phantom.  Using the LINAC to deliver the planned treatment, the 
dose at the centre of the water equivalent phantom was measured with an 
ionisation chamber and compared to the dose predicted by the Eclipse™ plan. 
 
To create a more complex situation, treatment plans were created for an 
anthropomorphic phantom placed on each of the immobilisation devices with 
fields passing through the immobilisation device.  Thermoluminescent dosimeters 
were inserted into the anthropomorphic phantom at precise positions to measure 
the dose delivered at various points within the treatment field.  The dose 
measured was then compared to the dose calculated by Eclipse™. 
 
Chapter four describes the materials and methods used to investigate the dose 
beyond large air gaps.  Large air gaps that can be created by an immobilisation 
device were simulated using water equivalent slabs supported above a water 
phantom.  The dose beyond the air gap was measured using a parallel plate 
ionisation chamber in the water phantom. The measured results were then 
compared to the dose predicted by Eclipse™.  A discussion of the results is also 
included. 
 
Chapter five contains a summary of the results from the two studies, a discussion 
of how the results correlate and the conclusions drawn, with a suggestion of 
further work that may be continued relating to this project.   
 
Chapter six contains the references used throughout this project.   
 
Chapter seven contains the Appendices, including further information relating to 
the Eclipse™  TPS and an extended set of results. 
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1.2 Papers Presented 
 
Papers presented during the course of this project include the following: 
 
A. Gray*, R. Bromley, L. Oliver, J. Martland, P. Johnston.  Verification of the dose 
calculated in an Eclipse™ treatment planning system when an immobilisation 
device is included in the body contour.  Engineers and Physical Scientists in 
Medicine Conference, Noosa, Sunshine Coast, Queensland, 17-21 September 
2006.  
 
A. Gray*, R. Bromley, L. Oliver, J. Martland, P. Johnston.  Verification of the dose 
calculated in an Eclipse™ treatment planning system when an immobilisation 
device is included in the body contour.  ACPSEM ACT/NSW Branch Research 
Committee MedPhys06. Institute of Medical Physics, School of Physics, 
University of Sydney. 1st December 2006. A copy of the presentation can be 
found in Appendix 7.1. 
 
A. Gray*, L. Oliver, S. Brown and P. Johnston. Perturbation of dose caused by 
large air gaps created by patient positioning devices. 9th Biennial ESTRO 
Meeting on Physics and Radiation Technology for Clinical Radiotherapy. 
Barcelona, Spain, 10-13 September 2007. Abstract accepted. 
 
A. Gray*, L. Oliver, S. Brown, P. Johnston. Dose perturbation caused by large air 
gaps created by immobilisation devices. Engineers and Physical Scientists in 
Medicine Conference, Fremantle, Western Australia, 14-18 October 2007. 
Abstract accepted. 
 
* Presenter 
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2 Background 
 
This chapter describes the process of radiation therapy, the accuracy achievable 
throughout the process, the relevant aspects of the Eclipse™ TPS and the dose 
calculation algorithm used throughout this study.  It also contains a review of the 
published literature regarding the dosimetric effects of objects outside the patient 
as well as the ability of TPSs to calculate the dose within and beyond low density 
media and air gaps.  
 
2.1 The Process of Radiation Therapy 
 
The process of radiation therapy using a LINAC involves many steps, including: 
 
• Diagnosis and clinical evaluation: 
o tumour pathobiology, 
o staging, 
o site and extent of the disease, 
o condition of the patient and 
o all clinical imaging and test information; 
• Therapeutic decisions: 
o cure/palliation, 
o treatment modalities; 
• Treatment simulation and imaging for treatment planning: 
o X-rays, 
o 3D imaging (CT scans, MRI) and 
o functional imaging (SPECT, PET); 
• Anatomical volume localisation and 3D contouring based on digital 
imaging information for: 
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o the patient’s anatomical volume, 
o the tumour volume (target site) and 
o critical structures of normal tissue; 
• Treatment planning to: 
o determine the optimum treatment configuration (beam modality, 
energy, direction, size, shape, intensity and dose),  
o compute the dose distribution and 
o compute the number of monitor units required for each field; 
• Fabrication of treatment aids such as: 
o compensators, 
o bolus, 
o shielding blocks; 
• Treatment:  
o the prescription is typically for daily treatments delivered over 
several weeks; 
• Verification of treatment set up by imaging during the prescribed course of 
treatment; 
• Patient clinical evaluation during and follow up after treatment (Van Dyk 
1999). 
 
Immobilisation devices may be used to place the patient in a specific position 
which allows optimal beam access, assist in providing a reproducible set up 
and/or limit patient motion (Podgorsak 2003, Van Dyk 2003, Khan 2007).  
 
Modern immobilisation devices include: 
 
• Head and neck or body casts made of: 
o polyurethane foam such as the Alpha Cradle™, 
o vacuum bags filled with tiny polystyrene balls, 
o thermoplastic moulds: solid or mesh sheets which can be heated 
and shaped around the patient which then become rigid when 
Page 27 of 169 
cooled  (these moulds are attached to the treatment couch or a 
plastic board placed under the patient). 
• Hand grips or overhead arm positioners: typically used during breast 
thorax or abdomen treatments to maintain the arms either above the head 
or beside the body in a well defined position. 
• Tilted boards, often with built in hand grips or arm supports: typically used 
for lung or breast treatments. 
• Prone breast boards: where the breast to be treated hangs through a cut 
out section of the board. 
• Belly boards: consisting of a foam cast or foam sections on a frame with a 
hole for the patient’s belly.  They are designed for obese patients or to 
reduce the amount of small bowel being irradiated in pelvic treatments. 
• Bite blocks: a type of immobilisation device used for head and neck 
treatments. A dental impression is attached rigidly to a base plate. 
• Stereo-tactic frames: used for treatments which require high precision, 
where standard immobilisation techniques are inadequate. The frame is 
attached to the patients head during the entire treatment procedure. It can 
be attached invasively e.g. using screws into the patients skull, or non-
invasively e.g. using a dental mould as a mouth grip (Podgorsak 2003, 
Khan 2007).  
 
During the treatment simulation stage, images of the patient in the treatment 
position, with these devices in place, are taken.  Most patients require CT scans 
to obtain a full 3D description of the patient’s anatomy and electron density data 
for calculation purposes by the TPS.  The TPS may assume that everything 
present in the CT image will be present during the treatment.  Any objects in the 
CT image, such as the CT couch or surface markers that are normally not 
present during the treatment, will interfere with the dose calculation. These 
objects need to be identified so that the TPS will ignore them during the dose 
calculation.  Alternatively, some TPSs, such as Eclipse™, require a structure to 
be defined to indicate what should be included in the dose calculation. 
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During the treatment planning stage, the beam modality (photon or electron) and 
energy are chosen.  For photon beams, the energy is given in units of megavolts 
(MV).  The photon beam produced is not mono-energetic.  For example, a beam 
designated as 6 MV, is a beam with a heterogeneous photon beam spectrum 
which has been produced by 6 MeV electrons striking a target within the LINAC.  
It consists of a spectrum with photon energies ranging from zero to 6 MeV (Van 
Dyk 1999). 
 
The result of the dose calculation is given as a dose distribution which can be 
overlayed and viewed on the CT images. The TPS calculation output also 
provides details of the total dose to the prescription point and the number of 
monitor units required for each treatment field to deliver the dose distribution for 
the particular set up.  
 
Monitor units are the units in which the dose is measured by an ionisation 
chamber within the LINAC before passing through any beam shaping or 
modifying devices such as the beam defining collimators.  At Royal North Shore 
Hospital (RNSH), the ionisation chamber within the LINAC is calibrated such that 
one monitor unit equals one centigray at the depth of dose maximum in a water 
phantom for a 10 x 10 cm2 field size, 100 cm source to surface distance (SSD).   
 
Fields may be required to pass through an immobilisation device during the 
patient’s treatment and may also pass through large air gaps created by the 
immobilisation device. The TPS dose calculation algorithm needs to accurately 
account for the attenuation due to the device and any changes in the dose 
distribution in order to calculate the dose to within clinical tolerances.  
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2.2 Tolerances for the Accuracy of Dose Calculations 
 
The accuracy that is achievable throughout the process of radiation therapy 
depends on the uncertainty in the following areas:  
 
• Absorbed dose measurement to a reference point in a water phantom, 
• Measurement of relative dose at points other than the reference point, 
• Relative dose calculations (conducted by the TPS during the treatment 
planning stage), 
• Patient treatment (e.g. due to patient set up reproducibility, patient 
movement during treatment, organ motion, the LINACs beam monitor 
stability and beam flatness) (Van Dyk 1999, AAPM Report no. 85 2004, 
Khan 2007). 
 
The ICRU recommends that the absorbed dose to the target volume should be 
delivered to an accuracy of 5% or better (ICRU Report 24 1976). This means that 
the accuracy for each of the plan and treat steps must be better than 2.5% (Van 
Dyk 1999).  Immobilisation devices assist in maintaining this accuracy throughout 
the whole planning and treatment process (Van Dyk 1999). 
 
Tolerances for the accuracy of dose calculations by a TPS have been published 
by a variety of authors (Van Dyk et al 1993, Fraas et al 1998, Venselaar et al 
2001).  All of the points investigated in this study were in high dose, small dose 
gradient regions. For the simple cases, central axis points were investigated and 
for the complex cases, off axis points were investigated.  Based on the 
tolerances published by Venselaar et al (2001), tolerances of 2% for the 
homogenous simple cases, 3% for simple cases with inhomogeneities and 4% 
for the complex cases are recommended.  
 
The documentation for the Eclipse™ TPS states that the PBC algorithm 
calculates the dose distribution with the following accuracy: 
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• Photon fields in typical clinical set up: 2-3% 
• Photon beam reconstruction model: ±1% (rectangular fields), ±2% 
(irregular fields) 
• Oblique correction within 1-2% (Varian Medical Systems 2003b). 
 
Based on the recommendations above and the expected accuracy of the 
Eclipse™ PBC algorithm, the lower tolerances of 2% for the simple homogeneous 
cases and 2.5% for complex cases with inhomogeneities were used throughout 
this project. 
 
2.3 The Eclipse™ Treatment Planning System 
 
Eclipse™ is a radiation therapy treatment planning system available through 
Varian Medical Systems. During this project Version 6.5 of the Eclipse™ External 
Beam Planning software was used.    Vision™ is a Varian image and plan 
management application used in conjunction with Eclipse™ at RNSH. The 
information provided in this section is primarily from the documentation provided 
with the Eclipse™ and Vision™ applications. 
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2.3.1 The Body Structure 
 
The Eclipse™ TPS requires that a body structure be defined for dose and MU 
calculation.  The body structure represents a 3D volume describing the site of the 
patient’s body in the images.  It is composed of stacks of contours in parallel 
slices of the 2D image view (Varian Medical Systems 2003a).  Throughout this 
thesis, the green shading in the CT images represents the body structure which 
has been contoured.  Figure 2.1 illustrates an example of a body structure which 
excludes external objects.  
 
 
 
Figure 2.1 CT scan of anthropomorphic phantom with mask and head extension 
board with a body structure (green shading) including only the phantom. 
 
The body structure identifies for Eclipse™ the image information which should be 
included in the dose and MU calculations. The dose algorithm for external photon 
beams uses the body structure to determine the source to surface distance, 
depth to the reference point and the effective depth.  For these calculations, the 
algorithm only considers areas that are inside the body structure or within bolus 
which has been added to the surface of the body structure using software tools in 
the TPS.  The dose distribution is only calculated for areas within the body 
structure and bolus (Varian Medical Systems 2003c). 
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All scanned objects located outside the body structure, such as an immobilisation 
device or the CT scanner couch do not influence the Eclipse™ photon dose 
calculations. Figure 2.2 shows the lack of effect when part of an object is not 
included in the body structure, compared to when the external object is included 
in the body structure. 
 
(a)        (b)  
 
Figure 2.2 Effect of part of an object not being included in the body structure.  
The upper part of the object is not included in the body structure on the left image 
(a) but is included in right image (b). 
 
2.3.2 Incorporating Objects Outside the Body Structure 
 
The Vision™ Calculation Algorithms manual (Varian Medical Systems 2003b) 
provides instructions for taking into account some objects which are in the beam 
path which are not included in the body structure.  These include wedges, 
compensators, multi-leaf collimators (MLCs), blocks and block trays.  
Adjustments are made to the dose calculation for example, by altering the 
relative dose distribution (e.g. using a dose profile measured beyond a wedge) 
and/or by altering the MUs to be delivered according to a central axis 
transmission factor to correct for attenuation of the beam.  
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The transmission factor is calculated by dividing the measured dose with the 
device in the beam path, by the dose measured without the device in the beam 
path for a standard set up (e.g. 10 x 10 cm2 field size, 100 cm SSD). An example 
of a device where a transmission factor can be used is a block tray.  Block trays 
are used to attach beam attenuating blocks to the LINAC to shape the beam. A 
block tray, with and without a block is shown in Figure 2.3.   
 
  (a)   (b)  
 
Figure 2.3 Block tray, with (a) and without (b) a block in place. 
 
The transmission factor is only valid for the conditions under which the factor was 
measured e.g. energy, field size and object location relative to the radiation 
source (such as distance from source and angle of beam incident on the object).  
The factor is only measured at one depth and radial line from the target source 
and is then applied to the entire dose distribution by altering the MUs required for 
the field.  If any changes occur in the physical conditions governing the dose 
distribution (such as what may occur at the surface of the patient in the build up 
region) the transmission factor and dose algorithm will not take this into account. 
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As transmission factors change the MUs but do not change the dose distribution, 
they cannot be used to account for sections of non-uniform thickness devices. 
Figure 2.4 illustrates the effect a transmission factor has on a plan. It can be 
seen that the dose distribution remains the same after applying the transmission 
factor and that only the MUs have changed.  
 
(a)       (b)  
 
Figure 2.4 An illustration of the effect of applying a transmission factor on the 
dose distribution and MUs. The dose distribution with (a) and without (b) the 
transmission factor applied is shown.  
 
Apart from when bolus is added during the treatment planning stage, no 
instructions are provided in the Eclipse™ manuals regarding corrections to 
account for beam transmission through any form of object that may be in contact 
with the patient. The effect on the dose delivered due to the treatment couch or 
an immobilisation device which is in contact with the patient is of specific concern 
in this work. 
  
If the beam transmission through the device can be approximated as uniform, a 
transmission factor may be applied in a similar way as when a block tray 
transmission factor is applied. 
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Figure 2.5 shows an example of a mask and head extension board used to 
immobilise the patient’s head during treatment.  A transmission factor can be 
used to account for the effects of the carbon fibre grid section of the board which 
is between the radiation source and patient.  
 
 
 
Figure 2.5 An example of a treatment through a head extension board where a 
transmission factor could be applied. 
 
There are occasions when the treatment beam is required to pass through an 
immobilisation device of non-uniform thickness or density. In this case a ‘blanket’ 
transmission factor which is applied for all points within the field cannot be used.  
Figure 2.6 shows a picture of a post axilla field passing through a non-uniform 
section of a breast board. It can be seen that the thickness of the board varies 
across the treatment beam area.  
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(a)    (b)  
 
Figure 2.6 A 3D reconstructed image (a) and beams eye view (b) of a patient on 
a breast board where the beam passes through varying thickness of a breast 
board. 
 
Eclipse™ is not able to account for two-dimensional attenuation of non-uniform 
objects, such as the breast board, in the dose calculation using a transmission 
factor.  When a field is passing through a non-uniform device, one possible 
solution is to include the immobilisation device in the body structure used for the 
TPS dose calculation. An example of a body structure which has been extended 
to include an immobilisation device is shown in Figure 2.7. 
 
 
 
Figure 2.7 A example of a body structure which has been extended to 
incorporate a head extension board, head rest and face mask. 
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2.3.3 The Eclipse™  Dose Calculation Algorithm 
2.3.3.1 Pencil Beam Convolution Algorithm 
 
The version of Eclipse™ used for this project utilises a PBC algorithm for the 
photon dose calculation.  The ETAR inhomogeneity correction method is used for 
the dose calculations in this study.  This section contains a brief description of 
the algorithm and ETAR inhomogeneity correction method focusing on the 
deficiencies which may result in inaccurate dose calculations for the situations 
investigated in this study. A detailed description of the dose calculation algorithm 
and ETAR method of inhomogeneity correction is provided in Appendix 7.2.   
 
Many different dose calculation algorithms are used in modern TPSs.  
Historically; two approaches to photon dose calculations have been taken, with 
the calculations either correction or model based.  Correction based methods 
calculate a dose distribution in water and then apply an inhomogeneity correction 
factor to account for any change in tissue and electron density.  Model based 
methods rely on the fundamental physics of scattering. The most advanced 
technique is the Monte Carlo method where the statistical interaction histories of 
millions of photons as they interact with matter are traced (Van Dyk 1999, IAEA 
TRS no. 430 2004).   
 
The Eclipse™ PBC algorithm is a correction based method and computes the 
calculation in two phases.  In the first phase, the dose is calculated in a 
homogenous water equivalent medium with treatment beam accessories such as 
MLCs and wedges taken into account.  As calculating the dose to the entire 
volume would be time consuming, the convolution is used to calculate the dose 
in five planes perpendicular to the beam and the dose for the other points in the 
volume is interpolated.  The second phase applies the patient model (based on 
the body structure contoured) to account for the actual skin curvature and 
inhomogeneities (Varian Medical Systems 2003a).   
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In the Eclipse™ PBC algorithm, the convolution given in Equation 2.1 sums a 
number of pencil beams, each weighted with field intensity to obtain the total 
dose contribution.  
 
''),','()''()','();,,( int dydxzyyxxKzyxPyxFFzyxD −−= ∫∫  
Equation 2.1 
 
Where D(x,y,z;F) is the dose at a point (x,y,z) for a field F, F(x’,y’) is the field 
intensity function, Pint(x’,y’,z) is the intensity profile (normalised fluence of primary 
photons at depth z) and K(x-x’,y-y’,z) is the pencil beam kernel for the 
combination of scattering element (x’,y’,z) and dose point (x,y,z) (Van Dyk 1999, 
Varian Medical Systems 2003b).   
 
The kernels are assumed to be invariant throughout the irradiated volume, not 
accounting for changes due to heterogeneous tissue, local changes in primary 
fluence or changes in the spread of energy due to local scattering.  This 
assumption results in faster calculations at the expense of accuracy (Van Dyk 
1999). 
 
The dose is then translated to account for any difference in the distance of the 
field central axis to the surface of the water equivalent material geometry 
compared to the patient geometry.  The patient model is then applied and the 
absorbed dose calculated using Equation 2.2. 
 
inhoa CCFzyxPFzDFzyxD ×××= );,,();();,,(  
Equation 2.2 
 
Where Da(z;F) is the depth dose of the irregular field along the effective field axis, 
P(x,y,z;F) is the off axis ratio, computed by interpolation along the fan lines, Co is 
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the correction factor for skin obliquity and Cinh is the correction factor for tissue 
inhomogeneities (Varian Medical Systems 2003b). 
 
2.3.3.2 The Equivalent Tissue Air Ratio Inhomogeneity Correction 
Method 
 
The inhomogeneity correction used throughout this study was the ETAR method, 
which was first introduced by Sontag and Cunningham in the late 1970s (Sontag 
and Cunningham 1977, Sontag and Cunningham 1978).  As conducting the 
calculations over the entire irradiated volume resulted in large computer memory 
requirements and calculation times, an approximation procedure was developed 
which reduced the summation to be over a single effective slice that produces 
the same scattering as all the slices taken together.  Details of the calculation 
procedures and assumptions are given in Appendix 7.2. 
 
As the ETAR method relies on tissue air ratio (TAR) measurements which are 
conducted under conditions approximating electronic equilibrium (where the 
energy carried in and out of the volume by electrons is equal), electron 
interactions which occur away from the photon interaction site are ignored.  It 
therefore cannot predict situations of electronic disequilibrium such as in the build 
up region and at points closer to the field edge than the range of secondary 
electrons (Metcalfe et al 1993).  
 
The assumption of electronic equilibrium is appropriate for lower photon 
energies, such as from cobalt 60 (approximately 1.25 MV).  However at the 
higher photon energies now more commonly used for radiation therapy such as 6 
MV, where the electron range can be up to several centimetres, it can lead to 
significant errors in dose calculation.  This is especially noticeable in low density 
regions where the electron range is increased and large overestimates in dose 
can arise (Metcalfe et al 1993).   
Page 40 of 169 
 
Electronic equilibrium can only truly occur when there is no attenuation of the 
primary beam. It can effectively occur when the percentage attenuation occurring 
over the distance equal to the range of electrons is small (Johns and 
Cunningham 1983). For simplicity, in the discussions throughout this thesis, 
electronic equilibrium is assumed to occur for points in the central axis of a 6 MV 
beam incident on a water equivalent material with a field size of at least 5 x 5 cm2 
in areas beyond the build up region and at least 5 cm from the distal surface of 
the water equivalent material. 
 
The situations investigated in this study involved beams passing through air gaps 
and low density regions within the immobilisation devices and patient, so errors 
within and surrounding the air gaps and low density media were expected.  The 
types of errors expected are described in more detail in Section 2.6 where the 
published studies on dose calculations within and surrounding air cavities and 
low density inhomogeneities are reviewed. 
 
2.4 Dosimetric Effects of Objects Outside the Patient  
 
Objects placed in the beam path between the LINAC radiation source and 
patient’s surface may significantly alter the dose distribution produced.  These 
can be items placed on the LINAC to intentionally modify the beam such as 
blocks supported by plastic trays, wedges or compensators, or they can be items 
used for patient set up such as the treatment couch or immobilisation devices, 
where modification of the dose distribution is not intended. 
 
When there are no objects placed in the beam path, the maximum dose received 
by high energy x-rays, such as 6 MV photons, is not at the surface.  This effect is 
called skin sparing and is due to the electrons which are set in motion having a 
range of several millimetres.  This effect is desirable for radiation treatments 
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where radiation dose to the skin is not required or where the skin is a dose 
limiting structure.   
 
Although lower than the maximum, the surface dose is not negligible; most of the 
surface dose is caused by electrons produced by beam modifying devices within 
or attached to the LINAC, such as collimators, blocks and block trays.  These 
electrons have a long range in air and the electrons with the lowest energy cause 
dose to be deposited at the skin surface.  Some surface dose is also caused by 
electrons produced in the air between the LINAC and the patient, electrons 
backscattered from photon interactions in the patient and from the exit dose from 
opposing beams (Metcalfe et al 1997).   
 
Devices placed against the patient’s skin can also increase the skin dose; the 
majority of studies investigating the dosimetric effects of immobilisation devices 
have investigated this effect, with only a few investigating transmission effects. 
Typically only beams incident perpendicular to the surface were investigated.  
The only study found that investigated incorporating the immobilisation device 
into the dose calculation was Munjal et al (2006). 
 
The following sections review the published literature on the dosimetric effects of 
objects outside the patient.  Methods for accounting for the effects of complex 
objects outside the patient are also introduced. 
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2.4.1 Immobilisation Devices 
2.4.1.1 Thermoplastics 
 
Most of the studies on immobilisation devices have investigated the effect of 
thermoplastics, which are used to create face masks or body moulds, on skin 
dose (Fiorino et al 1992, Fiorino et al 1994, Fontenla et al 1994, Mellenberg 
1995, Meara and Langmack 1998, Carl et al 2000, Sharp et al 2005).  
 
It has been found that the surface dose increases with increasing thermoplastic 
thickness and decreasing perforation size (Fiorino et al 1992, Fiorino et al 1994, 
Fontenla et al 1994, Carl et al 2000); increasing from 15% of the dose maximum 
to 57% for a 2.0 mm thick solid thermoplastic, 50% for a 2.0 mm thick perforated 
thermoplastic and 28% when the perforated thermoplastic was stretched to a 
thickness of 1.3 mm (6 MV, 10 x 10 cm2 field size, 100 cm SSD) (Carl et al 
2000).  
 
For measurements conducted using unstretched thermoplastics, it has been 
noted that while the thickness is typically less for patient set ups, the skin dose 
value obtained through unmoulded thermoplastic could be considered the 
maximum skin dose value when the skin is a dose limiting structure (Fiorino et al 
1994). 
 
The surface dose behind thermoplastics increases with increasing field size; from 
52.3% of the dose maximum (5 x 5 cm2) to 59% (15 x 15 cm2) for a 2.0 mm thick 
perforated thermoplastic (6 MV, 100 cm SSD) (Fiorino et al 1992).  The surface 
dose has also been found to decrease with increasing photon energy over the 
range from 4 MV to 15 MV (Mellenberg 1995, Meara and Langmack 1998, Carl 
et al 2000). No significant trend has been found for skin dose behind 
thermoplastics with changes in SSD (Fiorino et al 1992).  
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Transmission measurements have been conducted through a 2 mm thick 
thermoplastic by Meara and Langmack (1998) with transmissions of 98.6 to 
98.8% for 5-8 MV photons.   
 
Fiorino et al (1992) investigated combinations of thermoplastic materials with the 
use of wedges and block trays, finding that the addition of a tray increased the 
surface dose behind the thermoplastic from 60.1% to 64.3% of the dose 
maximum (6 MV, 15 x 15 cm2 field size, 85 cm SSD).  The addition of a 30o 
wedge decreased the surface dose measured.   
 
Considering the multiple variables affecting the skin dose behind thermoplastics, 
no simple method of applying factors to accurately determine skin dose in a 
clinical setting could be created.  If a TPS could accurately model the dose in the 
region immediately behind the thermoplastic, skin dose could then be assessed 
during the planning stage and modifications to the plan or set up be taken prior to 
starting treatment. Alternatively, to avoid the increase in skin dose, the section of 
a thermoplastic mould where the beam passes through may be cut out if the 
immobilisation capability of the mask is not compromised (Fiorino et al 1992, 
Podgorsak 2003, Khan 2007). 
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2.4.1.2 PMMA Boards 
 
PMMA boards, which are often used in conjunction with thermoplastic moulds as 
a fixation point, have also been investigated (de Mooy 1991, De Ost et al 1997, 
Meara and Langmack 1998, Munjal et al 2006).  For 6 MV beams, the skin dose 
has been found to increase from 14.8% for an open field to 97.7% when a 1 cm 
PMMA board is present (Meara and Langmack 1998).  For a 12.5 mm PMMA 
board the depth of dose maximum has been found to shift by 12 mm towards the 
surface and 96% transmission was measured (De Ost et al 1997).   
 
The variation of transmission factor for a 12 mm PMMA board with incident beam 
angle has also been investigated, with and without an air gap between the 
PMMA board and the phantom (Munjal et al 2006).  When the PMMA board was 
in contact with the phantom, the transmission through the board was found to 
vary between 95.2% (0o beam incidence) and 89.5% (60o beam incidence) (6 
MV, 10 x 10 cm2 field size).  When an ~8 cm air gap was present between the 
PMMA board and phantom (positioned using foam blocks and a thermoplastic 
cast), simulating head and neck geometry, the transmission was found to vary 
between 94.2% (0o beam incidence) and 92.6% (50o beam incidence).  
 
As most TPSs do not have the ability to account for transmission factors for 
obliquely incident beams, Munjal et al (2006) also investigated the ability of the 
PLATO-SUNRISE  TPS to model a PMMA board supported approximately 8 cm 
above the phantom.  When the PMMA board was included in the contour drawn, 
i.e. included in the dose calculation, the TPS calculated the dose to within 1.5% 
of measured values at the centre of the phantom.  When the PMMA board was 
not included in the calculation, the measured dose was up to 8.1% lower than the 
calculated dose (6 MV, 10 x 10 cm2 field size).    
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2.4.1.3 Polystyrene and Polyurethane Foam and Vacuum Bags 
 
The effects of polystyrene and polyurethane foam and polystyrene bead vacuum 
bags have been investigated by Johnson et al 1995, Mellenberg et al 1995, 
Meara and Langmack 1998 and Carl et al 2000.  All studies found that the skin 
dose increased with increasing thickness of the foam or vacuum bag.  For 
example, Carl et al (2000) found that the surface dose behind 1 cm and 4 cm 
thick sections of a polystyrene bead vacuum cradle for a 6 MV photon beam was 
41% and 56% of the dose maximum respectively, compared to 15% for an open 
beam (10 x 10 cm2 field size, 100 cm SSD).  Mellenberg (1995) found that the 
increase in skin dose was proportional to the thickness and density of the 
material in contact with the skin. 
 
2.4.1.4 Other Immobilisation Devices 
 
Other studies have concentrated on specific immobilisation devices, such as 
Olch and Lavey (2002) who investigated attenuation through a modified VBH 
HeadFix Arc system, measuring attenuation of 2-4% through most components, 
but up to 15% through some solid carbon fibre sections.  Vieira et al (2003) 
investigated transmission through the Sinmed Posifix-4 head support on a 
carbon fibre grid couch and the Posirest-2 lung board on a composite carbon 
fibre/foam couch using an electronic portal imaging device.  The transmission 
through most sections of the devices were 95-97%, but transmission of 90% was 
measured behind the plastic pins used to fix the mask on the head support and 
arm rests on the lung board (6 MV, patient treatment fields). The worst case 
measured was for a posterior oblique field through a section of the couch frame 
and the head support where a transmission of 85% was measured. The arm 
rests on the Sinmed Posirest-2 lung board are similar to those on the Sinmed 
Posiboard™-2 used throughout this project (illustrated in Figure 3.6 (page 68)).  
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For some patients treated at RNSH, a post axilla field would pass through the 
pins used to attach the arm rests.    
 
2.4.2 Block Trays 
 
Large air gaps are sometimes created by immobilisation devices which support 
the patient above the treatment couch.  This problem is common when using 
tilted breast boards, head rests or knee supports.  For example, when a posterior 
field passes through the breast board used in this study, the beam may first pass 
through the treatment couch and/or the base of the breast board, a large air gap 
and then the tilted back support region of the board before entering the patient.  
Examples of patient treatments where air gaps are created by immobilisation 
devices, including the breast board, are illustrated in Figure 4.1 (page 96).  No 
studies were found in the literature that investigated the effect of posterior fields 
passing through a tilted board or that investigated the accuracy of a TPS to 
calculate the dose behind large air gaps (greater than 5 cm) such as those 
created by immobilisation devices. 
 
Recent publications on the dosimetric effects of block trays, which are attached 
to the LINAC head to support field shaping blocks, have been summarised in this 
section as those investigations are the closest to mimicking the large air gap 
created by the tilted board which was investigated in this study. 
 
2.4.2.1 Surface Dose 
 
A number of studies have investigated the increase in surface dose when block 
trays are used (Rao et al 1973, Mackie and Scrimger 1982, Purdy 1986, Fiorino 
et al 1992, Fiorino et al 1994, Sharma and Johnson 1994, Mellenberg 1995, 
Butson et al 1996, Kim et al 1998, Jursinic 1999, van Kleffens et al 2000).  
Generally the surface dose has been found to increase with increasing field size 
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(Rao et al 1973, Purdy 1986, Fiorino et al 1992, Fontenla et al 1994, Mellenberg 
1995, Butson et al 1996, Kim et al 1998) and decreasing SSD (Rao et al 1973, 
Purdy 1986, Fontenla et al 1994, Kim et al 1998).  The results from Rao et al 
(1973), which can be seen in Table 2.1, illustrate these trends.  
 
Tray Present SSD             (cm) 
Field Size      
(cm2) 
Surface dose        
(% of dose 
maximum) 
No 100 10 x 10 20% 
Yes 100 10 x 10 24% 
Yes 100 20 x 20 54% 
Yes 85 10 x 10 32% 
 
Table 2.1 Surface dose for a 6 MV photon beam when using a block tray (Rao et 
al 1973). 
 
The dose maximum has been found to shift towards the surface when block trays 
are used, from 11 mm without the tray to 9mm with the tray present (6 MV, 15 x 
15 cm2 field size) (Rao et al 1973).  Kim et al (1998) found that the skin dose off 
axis was similar to that on the central axis, slightly decreasing towards the edge 
of the field.  
 
While electrons produced in the LINAC collimator were absorbed by the tray, 
additional electrons were produced by the tray.  The changes in the build up 
region have been attributed to electron contamination produced above the block 
tray being attenuated, extra electron contamination being produced by the tray 
and the photon spectrum being changed slightly after interaction with the block 
tray material (Rao et al 1973, Butson et al 1996). The use of a metal filter on the 
patient side of the tray reduces the increase in surface dose resulting from the 
presence of the tray (Mackie and Scrimger 1982, Purdy 1986).   
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2.4.2.2 Transmission 
 
Various studies have investigated the factors that influence transmission factors 
for block trays (Sharma and Johnson 1994, Jursinic 1999, van Kleffens et al 
2000). The studies found that the transmission through the tray increased with 
decreasing tray thickness (van Kleffens et al 2000), increasing beam energy 
(Jursinic et al 1999) and increasing field size (Jursinic 1999, van Kleffens et al 
2000).  Van Kleffens et al (2000) found that there was no SSD dependence for 
SSDs equal to or larger than 80 cm, but found that the transmission varied with 
distance of the tray from the radiation source.  Sharma and Johnson (1994) 
found no dependence on the depth of measurement for tray factors, for depths 
between the depth of dose maximum and 15 cm.  
 
Many of these studies also investigated the effects of wedges (Fiorino et al 1992, 
Sharma and Johnson 1994, Mellenberg 1995, Kim et al 1998) or lead and 
gypsum compensators (Mellenberg 1995). 
 
2.4.3 Treatment Couches 
 
The use of carbon fibre couch inserts is now a well established method of 
reducing patient set up errors associated with couch sag (McCormack et al 
2005).  They also have the additional benefit of minimal attenuation and 
distortion of the surface dose compared to previously used materials such as 
PMMA or wood (De Ost et al 1997). 
 
As it is sometimes unavoidable that a treatment beam passes through the couch, 
investigations into the dosimetric effects of a variety of treatment couch materials 
have also been conducted.  The carbon fibre materials used to produce modern 
treatment couches are similar to those used to produce some rigid immobilisation 
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devices, such as the head extension, breast board and belly board used in this 
study.  The results from the treatment couch studies can therefore be applied to 
immobilisation devices. 
 
2.4.3.1 Carbon Fibre Composites 
 
The main treatment couch material investigated is a carbon fibre/low density 
material composite, where two thin layers of carbon fibre are on either side of a 
low density core, such as foam (de Mooy 1991, De Ost et al 1997, Meara and 
Langmack 1998, Carl et al 2000, Higgins et al 2001, Gillis et al 2005, 
McCormack et al 2005, Poppe et al 2007). 
 
For a perpendicularly incident beam, most studies have reported transmission 
through a carbon fibre/low density material composite to be between 99 and 
100% (de Mooy 1991, De Ost et al 1997, Meara and Langmack 1998).  However, 
the perpendicular transmission has been measured to be as low as 98.5%.  For 
an obliquely incident beam this reduced further to 97.7%  and reduced again to 
96% when a carbon fibre couch frame was in the beam path (Gillis et al 2005).  
McCormack et al (2005) measured slightly lower transmissions using a cylindrical 
phantom, attributing the differences to the reduced scatter component reaching 
the detector due to the air gap created between the couch and the phantom. 
 
Beyond carbon fibre composite materials, the depth of dose maximum has been 
found to shift by 3-5 mm towards the surface for a 6 MV beam (De Ost et al 
1997, Gillis et al 2005).  The skin dose from a 6 MV beam has been found to 
increase from 15% of the dose maximum for an open beam, to 43-51% beyond 
1.1 cm thick samples of carbon fibre composite materials and 66% for a 4.1 cm 
sample (Carl et al 2000). The surface dose has also been found to increase with 
field size, from 68% for a 10 x 10 cm2 field to 82% for a 40 x 40 cm2 field for an 8 
MV beam (Higgins et al 2001). 
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2.4.3.2 Solid Carbon Fibre  
 
Carl et al (2000) has investigated the skin dose behind 0.5 mm and 0.9 mm thick 
samples of solid carbon fibre. The skin dose measured for a 6 MV beam was 
25% and 31% of the dose maximum respectively compared to 15% for an open 
field. Munjal et al (2006) measured transmission behind an 8 mm thick sample of 
solid carbon fibre obtaining 96.3% for perpendicular incidence and as low as 
92.0% for oblique incidence using a 6 MV beam. 
 
2.4.3.3 Mylar & Carbon Fibre Grid or ‘Tennis String’ 
 
Transmission and skin dose behind Mylar covered carbon fibre grid and ‘tennis 
string’ couch tops have also been investigated (Butson et al 2002, Gillis et al 
2005, Munjal et al 2006).   A carbon fibre grid couch insert with Mylar covering is 
illustrated in Figure 2.8.  A ‘tennis string’ couch insert with Nylon mesh and a 
Mylar covering is illustrated in Figure 2.9.  
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Figure 2.8 Carbon fibre grid couch insert. 
(http://www.medtec.com/products/immobilization/couchinserts/MT-CL.htm). 
 
 
 
Figure 2.9 ‘Tennis String’ couch insert. 
(http://www.aktina.com/products_categories.cfm?CategoryID=2). 
 
Munjal et al (2006) measured transmission through a carbon fibre grid couch 
obtaining 98.8% for perpendicular incidence and as low as 97.0% for oblique 
incidence using a 6 MV beam.  The grid used in treatment couches is similar to 
the carbon fibre grid in the central region of the head extension board used in this 
study.   
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Butson et al (2002) measured peak and average skin dose behind carbon fibre 
grid and ‘tennis string’ couches using radiochromic film. For the carbon fibre grid 
couch, the peak dose behind the couch was 67% and the average dose was 
48% compared to 16% for an open field (6 MV, 10 x 10 cm2 field size).  For the 
‘tennis string’ couch, the peak and average doses were 43% and 35% 
respectively.  These doses were found to increase with increasing field size. 
 
Gillis et al (2005) measured transmission through a ‘tennis string’ couch insert to 
be 99.7% for a 6 MV beam.  A ‘tennis string’ style couch insert was used 
throughout the investigation into the dose beyond immobilisation devices 
described in Chapter 3. 
 
2.5 Accounting for the Dosimetric Effects of Objects Outside 
the Patient 
 
If a beam passes through an immobilisation device or treatment couch which is 
not accounted for in the TPS, undesired and unpredictable alteration of the beam 
penetration characteristics may result.  This can potentially lead to an increase in 
skin dose or an under-dosage due to unaccounted attenuation (Gillis et al 2005, 
Meyer et al 2001). 
 
To deal with this problem it is necessary to restrict beam angles, model the 
couch and/or immobilisation device in the TPS or construct the couch and 
immobilisation devices from a material which has no clinically relevant effects on 
beam attenuation. For the first two approaches, the position of the patient relative 
to the couch and immobilisation device needs to be fixed for each treatment 
fraction. 
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The following sections review the published literature regarding restricting 
treatment beam angles, modelling objects outside the patient in the TPS and the 
set up reproducibility achievable with a variety of immobilisation methods. 
2.5.1 Avoiding Beam/Couch Intersection 
 
One approach to dealing with the attenuation through a treatment couch is to 
restrict the gantry angles which can be used. There are only a few TPSs which 
have the capability to check for a possible collision between the treatment beam 
and the couch, therefore the restrictions may have to be implemented manually 
in the treatment planning process.   
 
Meyer et al (2001) investigated accommodating couch constraints in IMRT 
treatments.  The investigations were based on three common treatment couch 
types: the Elekta™ standard therapy table top (which has a central spine support 
at one end and two lateral supports at the other), a Varian™ Exact treatment 
couch (which has two carbon fibre support rails which can move laterally), and an 
Elekta™ C- arm therapy top (which has two rotatable C-arms supports). Seventy 
coplanar plans with five to nine equally spaced beams were used to evaluate 
each couch for beam - couch support collision. Initial beam paths intersected with 
the Elekta™ standard therapy table supports in 63% of plans and with the 
Varian™ Exact treatment couch supports in 34% of plans, resulting in 
adjustments to the plans being required. All the plans were able to be delivered 
using the C-arm couch. 
 
Gillis et al (2005) also mapped possible gantry table combinations for an Elekta 
C-arm couch and Sinmed Mastercouch (made of a carbon fibre/low density 
composite material) noting collision with the patient, collision with the table and 
beam intersection through various areas of the couch. 
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Including the physical properties of the treatment couch in the TPS dose 
calculation would eliminate the problem of unknown attenuation and reduce the 
need to restrict beam angles. 
 
2.5.2 Including Objects Outside the Patient in the Dose 
Calculation 
 
Munjal et al (2006) investigated incorporating a PMMA board in the dose 
calculation by a TPS (Section 2.4.1.2, page 44).  To allow the TPS to do this, the 
device must be included in the images taken during treatment simulation.  If you 
also want the TPS to model the treatment couch, then the couch on the CT 
scanner must be made of the same material as the treatment couch (Munjal et al 
2006).  Alternatively, an overlay for the CT couch made of the same material as 
the treatment couch can be used.  An example of a couch overlay is illustrated in 
Figure 2.10. 
 
 
 
Figure 2.10 Head extension couch overlay 
(http://www.medtec.com/products/immobilization/hn/type-s/default.htm). 
 
Another limitation is the bore size of the CT scanner, typically 70 cm, compared 
with the relatively unobstructed treatment set ups that can be achieved on a 
LINAC.  The maximum field of view achievable by the CT scanner may not be 
large enough to include the couch top, immobilisation device and the patient’s 
entire external contour.  This is particularly a problem for breast treatments on a 
Page 55 of 169 
tilted board, where the patient is elevated above the couch and their arms are 
raised above their head.  Large bore scanners do exist but budget constraints for 
many departments limit their availability (Hendee et al 2005). 
 
2.5.3 Reproducibility of Patient Position 
 
If the treatment plan requires that the couch supports be in a specific position 
during treatment and/or that the gantry angles be restricted to avoid interference 
with the couch supports, the patient must be in the same position relative to the 
couch during each treatment.  This may involve the use of additional fixation 
devices, such as lock bars, to attach the immobilisation device to the treatment 
couch in a specific position.  The position of the immobilisation device relative to 
the patient will also need to be fixed during each treatment particularly if the 
beam is passing through an immobilisation device.  To achieve the required 
patient positioning reproducibility relative to the couch and immobilisation device, 
additional information regarding the position of the immobilisation device may 
need to be recorded during the treatment simulation phase.  
 
The set up reproducibility should be known prior to conducting patient treatments 
through an immobilisation device.  In 1995, Verhey published a review of the 
literature summarising the capabilities of several popular immobilisation systems.  
He estimated the uncertainties to be as shown in Table 2.2. 
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Site Technique Treatment to Treatment 
Simulation to 
Treatment Alignment 
Pelvis, Abdomen 
Alpha Cradle™ or 
thermoplastic 
casts 
3 - 4 mm  Laser 
 Not immobilised 6 - 8 mm 6 mm Laser 
Breast Alpha Cradle™ or vacuum bag 3 mm  Light Field 
Thorax Not immobilised 4 mm 6 mm Laser 
Head, Neck Face mask with neck 2.5 - 4 mm  Laser 
 Mechanical 3 mm 2.5 mm  
 Bite block 4 mm 6 mm Laser 
Intracranial Not immobilised 3 mm  Laser 
 Face mask with neck 2.0 - 2.5 mm  Laser 
 Cranial fixation (stereotactic) <1 mm  Mechanical 
 Non invasive (stereotactic) 1 - 1.5 mm  Mechanical 
 
Table 2.2 Immobilisation capabilities for various treatment sites (Verhey 1995). 
 
Further studies have been conducted with other immobilisation devices since the 
review by Verhey (1995).  Lirette et al (1995) investigated the treatment set up 
reproducibility for tangential breast treatments conducted using a flat board with 
arm support.  They found that the treatment to treatment set up reproducibility 
was approximately 3 mm and the simulation to treatment set up reproducibility 
was less than 4 mm.  Occasionally large deviations of up to 23 mm were found, 
confirming the need for daily verification procedures.   
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Generally patient positioning devices assist with the reproducibility, however the 
use of a belly board to spare the small bowel in rectal cancer patients has been 
found to decrease the set up reproducibility when compared to un-immobilised 
prone patients.  The largest displacement found being in the anterior-posterior 
direction where the mean displacement went from 1.8 mm to 4.5 mm when the 
immobilisation device was introduced (Allal et al 2002). 
 
Verhey (1995) noted that the results summarised were obtained by examining 
the position of anatomical points on films taken before or during treatment and 
comparing them to equivalent points on simulator films or digitally reconstructed 
radiographs.  Verhey (1995) also commented that although this reflects the ability 
of the system to reposition skeletal anatomy the results may not translate to the 
ability of the system to reposition the target volume.   
 
The results of the studies may also not represent the reproducibility of the 
position of the immobilisation device relative to the patient.  This must be known 
if the immobilisation device is being incorporated into the dose calculation, 
particularly where a beam is passing through a region of the device where the 
attenuation is significant.  No studies have been found in a literature search 
describing the set up reproducibility of the immobilisation device relative to the 
patient. 
 
2.6 Investigations into Effects of Air Cavities and Low Density 
Inhomogeneities on Dose Calculations 
 
Immobilisation devices are often made out of low density materials, with the aim 
of making them as radiotranslucent as possible.  Some immobilisation devices 
may also result in air gaps being created between where the beam first intersects 
with the treatment couch or immobilisation device and when the beam enters the 
patient.  Large air gaps may be created when using a tilted board with posterior 
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fields.  Smaller air gaps may also be created when using head and neck 
immobilisation devices. Examples of air gaps which are created when using 
immobilisation devices can be found in Figure 4.1 (page 96). 
 
Typically the effects of air gaps and low density inhomogeneities have been 
investigated with respect to air cavities and low density material within the 
patient, such as the sinuses, nasal cavities, larynx and lungs.  The studies 
generally compared measured results or Monte Carlo calculations to dose 
calculations by a variety of algorithms and inhomogeneity correction methods. 
 
2.6.1 Air Cavities 
 
Air cavities within a patient are small compared to the air gaps that can occur 
when immobilisation devices are used.  The size of air gaps investigated in the 
studies to date reflect this focus: small rectangular (Young and Kornelsen 1983, 
Beach et al 1987, Wong et al 1992, Wong et al 1996, Kan et al 1998, Ding et al 
2004), triangular (Wong et al 1996) and cylindrical (Li et al 2000) cavities or 
channels.  Slab air gaps of up to 5 cm thick have also been investigated (Wong 
et al 1992, Shahine et al 1999, Li et al 2000, Ding et al 2004).   
 
A secondary build up region behind air cavities was observed in all interface 
region studies which was not accounted for by the ETAR correction method 
(Wong et al 1992, Wong et al 1996, Shahine et al 1999).  The dose reduction 
beyond the air cavity was found to increase as the air cavity size increased 
(Young and Kornelsen 1983, Wong et al 1992, Li et al 2000), as the field size 
decreased and as the x-ray energy increased (Wong et al 1992, Li et al 2000).  
The results from Wong et al (1992), shown in Table 2.3 and Table 2.4, display 
these trends.   
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Secondary Build Up Range (mm) 
6 MV 18 MV 
Air Cavity 
Thickness 
(cm) 
5 x 5 cm2 10 x 10 cm2 5 x 5 cm2 10 x 10 cm2 
1 2 2 4 2 
2 4 2 10 3 
3 8 2 16 10 
4 8 4 18 10 
 
Table 2.3 Secondary build up range (depth where electronic equilibrium is re-
established) measured using a Markus chamber for 100 cm SSD, 4 cm solid 
water before air gap (Wong et al 1992). 
 
Surface Dose Percentage Error 
6 MV 18 MV 
Air Cavity 
Thickness 
(cm) 
5 x 5 cm2 10 x 10 cm2 5 x 5 cm2 10 x 10 cm2 
1 -3.5 0.8 -5.1 -0.6 
2 -14.0 -1.8 -17.7 -4.5 
3 -25.6 -6.9 -29.0 -9.4 
4 -32.9 -10.3 -36.7 -13.4 
 
Table 2.4 Percentage errors at the distal surface of a slab air cavity between the 
experimental data obtained using a Markus chamber and the ETAR calculated 
values for 100 cm SSD, 4 cm solid water before air gap (Wong et al 1992). 
 
Li et al (2000) found that the dose reduction effects increased when the air cavity 
was situated at a smaller depth in water.  Build down effects before the air cavity 
have also been observed (Ding et al 2004).   
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Du Plessis et al (2001) investigated air cavities in a patient model based on CT 
scans.  For the maxillary sinus region, inaccuracies of 20-70% were measured 
using the ETAR correction compared to Monte Carlo calculations. 
 
As mentioned in Section 2.4.1.2 (page 44), Munjal et al (2006) investigated the 
ability of the PLATO-SUNRISE TPS to calculate the dose at the centre of a 
phantom where the field passed through a PMMA board, then an ~8 cm air gap 
before entering the phantom.   When the board and air gap were included in the 
dose calculation, the TPS calculated the dose to within 1.5% for all incident beam 
angles. The TPS consistently overestimated the dose but no comment was made 
regarding this systematic error.  No investigation into the accuracy of the dose 
calculation at the air/phantom interface for the set up was conducted.  This was 
the only study found that investigated the dosimetric effects of air gaps created 
outside the patient’s body by an immobilisation device. 
 
2.6.2 Low Density Inhomogeneities 
 
The studies into the effects of low density inhomogeneities mostly focused on 
dose within the lung or near the lung/tissue interface region beyond the lung 
(Young and Kornelsen 1983, Mackie et al 1985, Metcalfe et al 1993, Kappas and 
Rosenwald 1995, du Plessis et al 2001, Carrasco et al 2004, Ding et al 2004). 
They did not investigate depths of more than a few centimetres beyond the low 
density inhomogeneity.  Dose at a depth beyond a low density inhomogeneity 
may be required when a beam passes through an immobilisation device which is 
used for the patient set up.  This is not uncommon when using modern conformal 
and IMRT treatment techniques due to the increased number of gantry angles 
used. Studies investigating the accuracy of dose calculations in this situation 
were not found in a literature search. 
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Mackie et al (1985), Metcalfe et al (1993), du Plessis et al (2001), Engelsman et 
al (2001) and Carrasco et al (2004) investigated the ETAR method of 
inhomogeneity correction which is used in this study.  For high energy photon 
beams (such as 6 MV), calculations using the ETAR method of inhomogeneity 
correction have been found to overestimate the dose within and near low density 
media (Young and Kornelsen 1983, Mackie et al 1985, Carrasco et al 2004). The 
magnitude of the errors was found to increase when smaller field sizes and 
higher energy photon beams were used (Mackie et al 1985, Metcalfe et al 1993).  
The results from Metcalfe et al (1993), shown in Table 2.5, illustrate these trends. 
 
Percentage Difference between the ETAR Predicted Dose and Measured Dose 
Energy 6 MV 10 MV 18 MV 
Field Size (cm2) 5 x 5 10 x 10 5 x 5 10 x 10 5 x 5 10 x 10 
Mid Lung +7.2 -0.1 +6.4 +2.2 +10.8 +1.6 
Lung/Tissue 
Interface +6.5 +2.0 +6.7 +4.1 +10.6 +2.7 
 
Table 2.5 Percentage difference between the ETAR predicted dose and the dose 
measured with a thimble ionisation chamber in a 4 cm solid water / 8 cm solid 
lung / 4 cm solid water phantom (Metcalfe et al 1993). 
 
Lateral scatter and penumbra broadening in low density materials has also been 
observed, neither of which were accounted for by the ETAR correction method 
(du Plessis et al 2001, Engelsman et al 2001, Carrasco et al 2004). 
 
The difference between the measured and calculated results for both the air gap 
and low density inhomogeneity studies were attributed to electronic equilibrium 
not occurring at the point of interest, violating an assumption of the calculation 
method, that the point where the dose is calculated is located at a position where 
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electronic equilibrium exists (Mackie et al 1985, Metcalfe et al 1993, Wong et al 
1996).  
 
The loss of longitudinal and lateral electronic equilibrium is dependent on energy, 
radiation field size and the range of charged particles set in motion (increasing 
with increasing energy of the incident beam and decreasing density of the 
material) (Shahine et al 1999).  When the beam passes through a low density 
region, e.g. lung or air cavity, the primary transmitted radiation is increased as 
the lower density material attenuates the beam less.  However, there are fewer 
scattered photons created by the lower density material (reducing dose) and 
fewer electrons set in motion and the electrons which are set in motion have a 
greater range (Young and Kornelsen 1983, Shahine et al 1999).   These effects 
result in regions of electronic disequilibrium and also in electrons travelling 
outside the limits on the photon beam which degrades the beam profile (Young 
and Kornelsen 1983).  For low energies, such as those from cobalt 60 beams, 
the extent of regions where electronic equilibrium is not achieved is limited so the 
inaccuracies in the dose calculations are reduced (Young and Kornelsen 1983). 
 
Calculations using the ETAR inhomogeneity correction also only account for 
photon transport so they do not consider the transport of secondary electrons 
and therefore do not account for the effects observed (Metcalfe et al 1993, 
Shahine et al 1999, du Plessis et al 2001).   
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3 Investigation into the Dose beyond Immobilisation 
Devices 
 
This chapter describes dosimetry investigations of radiation therapy treatments 
involving photon beams passing through a variety of immobilisation devices for 
slab and anthropomorphic geometries.  This chapter describes in detail the: 
• equipment used; 
• treatment set-ups and imaging during simulation; 
• creation of the treatment plans; 
• radiation dose measured for the treatment plans and; 
• comparison of the measurements to the dose distribution calculated by the 
Eclipse™ TPS. 
 
The aim of this study was to confirm if Eclipse™ PBC dose calculation algorithm 
(with ETAR inhomogeneity correction) can calculate the dose distribution and 
MUs to within an acceptable clinical tolerance of 2.5%, when the treatment fields 
pass though a complex and/or low density immobilisation device which is 
included in the body structure.   
 
3.1 Materials 
3.1.1 Phantoms 
 
The Bailliere’s Australian Nurses’ Dictionary defines a phantom as a device for 
simulating the in vivo interaction of radiation with tissues (Burr et al 1991). They 
are used so that an image or dose measurement may be obtained under defined 
conditions of exposure. For measuring dose distribution data, water phantoms 
are often used. This is because water closely approximates the radiation 
absorption and scattering properties of soft tissue.  As it is not always possible to 
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conduct measurements in a water phantom, solid dry phantoms have been 
developed as substitutes for water. The aim is to have the same effective atomic 
number, number of electrons per gram and mass density as water (Khan 2003).  
 
Anthropomorphic phantoms are also commonly used for clinical dosimetry. The 
phantoms are the shape of a human head and torso, incorporate material to 
simulate muscle, bone and lung tissue and also have air cavities (Khan 2003). 
The use of anthropomorphic phantoms with thermoluminescent dosimeter chips 
for TPS validation has been described by Dunscombe et al (1996). The accuracy 
of the technique per measurement point is estimated to be 3% for dose (with low 
dose gradient) and 3 mm in positional accuracy (with high dose gradient). 
 
Two phantoms were used in this study, a water equivalent slab phantom and an 
anthropomorphic phantom. 
 
3.1.1.1 Slab Phantom 
 
Water equivalent RW3 (rigid water) slabs (PTW-Freiburg, Germany) and 
Certified Therapy Grade (CTG) solid water® slabs (Gammex RMI, Middleton, WI, 
USA) were used to create a homogeneous, cubic object to simulate a simple 
geometry treatment situation. These phantom materials are designed to simulate 
a water equivalent medium. 
 
The CTG solid water® slabs were 30 x 30 cm2 with varying thickness (1, 2 and 4 
cm).  The thickness tolerance of the slabs is ± 0.5 mm.  One of the slabs 
contained a cavity shaped to hold a 0.6 cm3 ionisation chamber in the centre of 
the slab. A solid water® insert designed to fill the cavity was used during the CT 
scans taken during the planning process.  An illustration of some CTG solid 
water® slabs can be found in Figure 3.1. 
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Figure 3.1 Certified Therapy Grade Solid Water® 
(https://www.gammex.com/catalog/product_info.php?cPath=35_56_60&products
_id=359&osCsid=b7d0104566ea29f2c28797ea701f0441). 
 
To supplement the solid water® slabs, water equivalent RW3 slabs were used to 
provide back scatter. The RW3 slabs were 30 x 30 cm2 and 0.1, 0.2, 0.5, and 1 
cm thick.  The thickness tolerance of the slabs is ± 0.1 mm. Some water 
equivalent RW3 slabs are illustrated in Figure 3.2. 
 
 
 
Figure 3.2 Acrylic and RW3 (Goettingen White Water) Slab Phantoms 
(http://www.ptw.de/acrylic_and_rw3_slab_phantoms.html). 
 
The overall phantom dimensions were 12 x 30 x 30 cm3, consisting of 7 cm total 
thickness of solid water® slabs placed on top of 5 cm total thickness of RW3 
slabs.  The slabs were arranged so that centre of the chamber cavity, with insert 
Page 66 of 169 
in place, was located at a depth of 5 cm. A schematic diagram of the phantom is 
shown in Figure 3.3. 
 
 
 
Figure 3.3 A schematic diagram of the slab phantom. 
 
3.1.1.2 Anthropomorphic Phantom 
 
A human shaped RANDO® anthropomorphic phantom (Alderson Labs, 
Stamford, CT, USA) was used to simulate a more complex treatment situation 
similar to the treatment of a human.  The phantom was configured to be a torso 
and head of an adult female and was constructed of tissue, lung and bone 
equivalent materials. The phantom was divided into 2.5 cm thick slices with 
removable plugs in which thermoluminescent dosimeters could be placed. A 
RANDO® anthropomorphic phantom is illustrated in Figure 3.4. 
 
 
7 cm 
5 cm 
 
5 cm 30 cm
30 cm
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Figure 3.4 RANDO® anthropomorphic phantom 
(http://www.phantomlab.com/rando.html). 
 
3.1.2 Immobilisation Devices 
 
The effects of four different immobilisation devices were investigated. They were: 
• a MEDTEC Contoura™ belly board; 
• a Sinmed Posiboard™-2 breast board; 
• a VacFix® vacuum bag and; 
• a MEDTEC Type-S™ head extension.   
 
The MEDTEC Contoura™ belly board is made of hollow core carbon fibre, and 
comes with three interchangeable padded inserts to customise bowel 
displacement (http://www.medtec.com/). A MEDTEC Contoura™ belly board is 
illustrated in Figure 3.5. 
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Figure 3.5 MEDTEC Contoura™ Belly Board 
(http://www.medtec.com/products/immobilization/hp/bellyboards.htm). 
 
The Sinmed Posiboard™-2 breast board (illustrated in Figure 3.6) is made of a 
low density foam core covered with a thin layer of carbon fibre.  The board can 
be positioned at eight different angles. The position of the arm supports and 
‘bottom stop’ can also be adjusted (http://www.sinmed.nl/). 
 
 
Figure 3.6 Sinmed Posiboard™-2 Breast Board (http://www.sinmed.nl/). 
 
The VacFix® vacuum bag consists of an airtight plastic bag containing polysterol 
microspheres.  The plastic cover is 0.15 mm thick. During the treatment 
simulation stage, the patient is set up in the treatment position with the vacuum 
bag placed around them.  The air is evacuated through a valve using a suction 
pump resulting in a rigid, close fitting cast (Jakobsen et al 1987).  Because of the 
air tight valve, the mould can maintain its shape throughout the course of 
treatment.  At the conclusion of the course of treatment, the valve is opened and 
the bag can be reused. Vacuum bags can be used over a wide range of 
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treatment areas (Khan 2007, Podgorsak 2003).  Various sizes of VacFix® 
vacuum bags are illustrated in Figure 3.7.  A large size vacuum bag was used 
throughout this study. 
 
 
 
 
Figure 3.7 VacFix® Vacuum Bag (http://www.ssxray.com/vacfix.html). 
 
The MEDTEC Type-S™ head extension (illustrated in Figure 3.8) consists of a 
head and shoulder base plate which extends off the end of the treatment couch.  
The shoulder support and head frame is made of carbon fibre with a low density 
core.  The treatment grid section is made of solid carbon fibre. 
(http://www.medtec.com/).  Head extension boards are used in conjunction with a 
face mask and neck support. 
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Figure 3.8 MEDTEC Type-S™ Head Extension 
(http://www.medtec.com/products/immobilization/hn/type-s/default.htm). 
 
3.1.3 Dosimetry Systems 
3.1.3.1 Ionisation Chamber 
 
To verify the dose within the slab phantom, an ionisation chamber and 
electrometer, with a calibration traceable back to the Australian primary standard 
at the Australian Radiation Protection and Nuclear Safety Agency was used.  The 
ionisation chamber was an NE Technology Limited (Berkshire, England), model 
2571, Farmer type cylindrical ionisation chamber. The chamber has a graphite 
wall and a cavity volume of 0.6 cm3.  The chamber was used in conjunction with 
a Keithley 35617 programmable dosimeter (Keithley Instruments Inc, Cleveland 
Ohio, USA) with the bias voltage set to -300 V. 
 
The electrometer readings were converted to absorbed dose using the formula 
given in Equation 3.1. 
 
QoQQowDQQw kNMD ,,,, =   
Equation 3.1 
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Where MQ is the dosimeter reading which has been corrected to the reference 
values of influence qualities, other than beam quality, such as temperature and 
pressure, for which the calibration factor is valid.  ND,w,Qo is the calibration factor 
in terms of absorbed dose to water of the dosimeter and KQ,Qo is the beam quality 
correction factor (IAEA TRS 398 2000).  
 
All measurements were repeated until the reading stabilised, using a minimum of 
three measurements.  The readings were corrected for daily LINAC output 
variations by conducting a constancy measurement under standard conditions of 
LINAC exposure during each session of experimental measurements. An 
average of the readings was used to determine MQ.  The relative standard 
uncertainty of Dw,Q is estimated as 1.5% (IAEA TRS 398 2000). 
 
3.1.3.2 Thermoluminescent Dosimeters 
 
To verify the dose within the RANDO® anthropomorphic phantom, 
thermoluminescent dosimeters (TLDs) were placed within hollow plugs in the 
phantom where the treatment fields passed through the phantom. The TLD plug 
replaced one of the tissue equivalent plugs for the measurement. An explanation 
of the theory of thermoluminescent dosimetry can be found in Khan (2003). 
 
The TLD chips used were Harshaw TLD-100 chips (Bicron, Solon, Ohio, USA).  
They were made of lithium fluoride doped with magnesium and titanium and had 
the dimensions of 3.2 x 3.2 x 0.89 mm3.  Four chips were used for each phantom 
measurement. The chips were aligned to form a rectangle 12.8 x 3.2 mm2, 
wrapped in thin plastic film (GLAD®WRAP) and placed between two halves of a 
hollow PMMA plug used for insertion into the phantom. The TLDs and plugs are 
shown in Figure 3.9. 
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Figure 3.9 Top left: Four loose Harshaw TLD-100 chips. Top right: Four Harshaw 
TLD-100 chips wrapped in thin plastic. Bottom left: two halves of a hollow plug 
used for containing TLDs in a RANDO® anthropomorphic phantom. Bottom right: 
a tissue equivalent plug used throughout a RANDO® anthropomorphic phantom. 
 
Prior to each TLD exposure, the chips were annealed to remove any residual TL 
signal from previous exposures.  The annealing process restores the original 
sensitivity and glow curve characteristics of each chip.  The pre-irradiation 
annealing program consisted of heating the chips at 400o C, remaining at 400o C 
for one hour, then applying a rapid cool to 100o C. The chips are then kept at 
100o C for two hours and then rapidly cooled to 45o C.  A programmable PTW-
TLDO annealing oven was used. 
 
The sensitivity of each TLD chip in a batch of 100 was calculated by irradiating 
the batch of TLDs in a Perspex slab phantom. One slab had a section with 
shallow indentations drilled into it, to allow the TLDs to be placed in 10 rows of 10 
TLDs positioned in the central region of the slab. The chips were irradiated using 
a 6 MV photon beam at the depth of dose maximum (12 mm in Perspex) with a 
field size sufficient to irradiate all the chips to the same dose. The sensitivity of 
each chip was calculated by dividing the average reading obtained for all the 
chips in the set by the reading obtained for the chip.   The sensitivity of each chip 
in the batch was obtained by averaging the sensitivity obtained from five repeat 
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experiments.  Only chips which produced reproducible results with a standard 
deviation of less than 2% were used for TLD measurements in this project.  
 
During each experimental TLD exposure, 12 chips from the TLD set being used 
were allocated to determine a calibration curve to convert the TL reading to dose.  
Using the Perspex slab phantom, three sets of four TLDS were exposed to a 
known dose, which encompassed the doses expected to be delivered to the 
TLDs. Calibration doses of 50, 150 and 250 cGy were delivered. 
 
The experimental and calibration TLD chips were read at the same time using a 
Harshaw 5500 TLD reader controlled with TLD Shell software (S-25089.006).  
The time-temperature settings used during the reading consisted of preheating 
the chips to 100o C in 15 seconds, then increasing the temperature at a rate of 
15o C/s until 300o C was reached.  The raw reading data was exported in ASCII 
file format into Microsoft Excel for analysis.   
 
First the raw readings were corrected according to their sensitivity. Then based 
on the readout from the 12 calibration TLDs, a calibration curve was generated 
(using a best fit 2nd order polynomial curve) for a range of exposures from 0 to 
250cGy.  If the R2 value for the best fit curve obtained was between 0.9999 and 
1.0000, the calibration curve was then used to calculate the dose delivered to the 
experimental TLDs.  The average dose measured by the four chips used for each 
phantom measurement was taken as the point dose at the centre of the plug. 
 
The accuracy of the use of anthropomorphic phantoms with TLD chips per 
measurement point is estimated to be 3% for dose (with low dose gradient) and 3 
mm in positional accuracy (with high dose gradient) (Dunscombe et al 1996). 
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3.2 Methods 
 
All experiments simulating radiation therapy treatments with an immobilisation 
device were conducted in 3 stages: 
i) simulation; 
ii) planning; and 
iii) treatment delivery. 
 
Experiments for each phantom were conducted with and without an 
immobilisation device in place to determine the effect of the device on the 
accuracy of the treatment plan dose calculation.  
 
i) Simulation 
A CT scan of the phantom with and without each immobilisation device arranged 
in the treatment set up was obtained using a GE lightspeed CT scanner (General 
Electric Medical Systems, Milwaukee, Wisconsin, USA). The phantom was 
aligned with the CT room isocentric lasers, which are maintained to be within 2 
mm of the CT isocentre as recommended by the ACPSEM (Millar et al 1997).  
These lasers identify the centre of the scan and allow the phantom to be set up in 
the same position during treatment using the treatment room lasers which 
identify the isocentre of the LINAC.  The position of the immobilisation device 
relative to the phantom was recorded and the position of the lasers was marked 
on the phantom and immobilisation device.  CT marker wires were placed on the 
phantom during the scan to allow the laser positions to be visualised on the scan. 
 
The CT scans were obtained with the standard settings used for a patient 
treatment with each an immobilisation device. The CT scanner settings consisted 
of a slice thickness of 2.5 mm, a peak voltage of 120 kV and a current of 
between 220 and 260 mA, depending on the treatment area. The field of view 
was extended from the default of 50 cm to the maximum of 65 cm to encompass 
the entire phantom and immobilisation device. 
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ii) Planning 
The CT scan data was exported into the Eclipse™ TPS to create plans for each 
treatment set up. Plans were created for the simulated patient and immobilisation 
devices for (i) a body structure including the phantom only when no 
immobilisation device was present, (ii) a body structure including the phantom 
only when there was an immobilisation device present and (iii) a body structure 
including the phantom and the immobilisation device.   
 
To create the body structure for the phantom only plans, the phantom was 
contoured using the ‘Search Body’ software tool in Eclipse™. This tool 
automatically contours the parts of an object with CT numbers within a range 
specified in the software as typical for human tissue.  The Eclipse™ TPS then 
processes the contour to fill in gaps within the contour not included in the original 
search, such as air cavities (Varian Medical Systems 2003d).   
 
To create the body structure for the phantom and immobilisation device plans, 
the phantom was contoured as for the phantom only plan.  Then an additional 
immobilisation device structure was created by drawing a bulk contour around 
the entire immobilisation device as indicated in the CT scan.  This contour 
included any air gaps created between the immobilisation device and phantom.  
The immobilisation device structure was then added to the body structure, using 
a ‘Boolean Operator’ software tool in Eclipse™, to create a new composite body 
structure which included both the phantom and the immobilisation device. 
 
Fields were added to the plans which passed through the immobilisation device 
in an identical fashion for both plans. All plans created during the investigation 
into the dose beyond immobilisation devices were planned for a 6 MV photon 
beam produced by a Varian CLINAC 2100C/D radiotherapy LINAC.  The 
Eclipse™ dose was calculated using the PBC_75143 algorithm, with a 2.5 mm 
calculation grid and the ETAR inhomogeneity correction. 
Page 76 of 169 
 
In Eclipse™, reference points are used for displaying, defining and prescribing 
the absorbed dose at specific locations (Eclipse™, Version 6.5 Instructions for 
Use, Treatment Planning). Reference points were created at locations inside the 
phantom and within the boundaries of the treatment fields.  One of the reference 
points was used as the prescription point whilst the other point(s) were selected 
at the locations where the dosimeter(s) would be placed for the subsequent 
measurements taken in the phantom during the treatment stage.    
 
iii) Treatment 
The CT scan phantom set ups were reproduced on the LINAC to simulate a 
patient treatment with the dosimeter(s) placed in the phantom in the position of 
the dose reference points in the treatment plan.  The phantom was aligned with 
the LINAC room isocentric lasers, which are maintained to be within 2 mm of the 
LINAC isocentre as recommended by the ACPSEM (Millar et al 1997).  TLDs 
were placed in the anthropomorphic phantom and an ionisation chamber in the 
slab phantom.  The treatment parameters of the plan were reproduced on the 
LINAC and the phantom exposed using the MUs calculated by Eclipse™. The 
measurements were then processed to determine the dose at each defined 
measurement point in the phantom. The result was compared to the Eclipse™ 
point dose calculated in the treatment plan. 
 
3.2.1 Slab Phantom Set Ups 
3.2.1.1 Without Immobilisation Device 
 
To provide a control measurement for the slab geometry case, plans were 
created for the slab phantom alone.   Three plans were created with one field 
each.  The field sizes used were 5 x 5 cm2, 10 x 10 cm2 and 20 x 20 cm2.  The 
fields were centrally placed and the phantom surface was set to 100 cm SSD. A 
dose reference point was defined where the centre of the ionisation chamber was 
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positioned for the measurement during the treatment stage.  Figure 3.10 
illustrates a plan created for the slab phantom alone.   
 
 
 
Figure 3.10 Plan created in Eclipse™ for the slab phantom alone. 
 
3.2.1.2 With Immobilisation Device 
 
For the experimental set ups, each of the four immobilisation devices was placed 
on top of the slab phantom and positioned with a central, but not necessarily 
uniform, section over the centre of the phantom.  Six plans were created for each 
of the immobilisation devices, three for when the body structure only included the 
phantom and three for when body structure included both the immobilisation 
device and the phantom.  Each plan used a single centrally located field of either 
5 x 5 cm2, 10 x 10 cm2 or 20 x 20 cm2.  The phantom surface was set to 100 cm 
SSD and a dose reference point was defined at the centre of the cavity for the 
ionisation chamber. 
 
Two regions of the head extension were chosen to investigate its beam 
attenuation properties. The solid shoulder support region and the grid section of 
the head support.  One region of each of the other immobilisation devices was 
investigated for their attenuating affects.  The set up for the shoulder region of 
the head extension is illustrated in Figure 3.11. Figure 3.12 illustrates two of the 
plans created for the shoulder region of the head extension board.    
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Figure 3.11 The set up for the shoulder support region of the head extension 
board on the slab phantom. 
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(a)  
 
(b)  
 
Figure 3.12 Plans created in Eclipse™ for the shoulder region of the head 
extension board with only the phantom included in the body structure (a) and with 
the phantom and the immobilisation device included in the body structure (b). 
 
3.2.2 RANDO® Phantom Set Ups 
3.2.2.1 Without Immobilisation Device 
 
To simulate a patient treatment where a field directly enters the patient, three 
plans were created using the RANDO® phantom.  Plans were created to 
simulate a 10 x 10 cm2 field passing through lung, bone and tissue areas. 
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A dose reference point was selected to correspond with the centre of where the 
TLD plug was located for measurement during the treatment stage.  The location 
for the TLD measurement was carefully chosen to be within the treatment area 
where the dose gradient was less than 2.5% across the TLD plug and in lung, 
behind bone and in tissue respectively.  Figure 3.13 shows the plans created for 
the tissue and bone fields.  The blue cross represents the position of the dose 
reference point for the plan. 
 
(a)      
 
(b)  
 
Figure 3.13 The plans for the RANDO® phantom with fields passing through 
tissue (a) and bone (b). 
 
3.2.2.2 With Immobilisation Device 
 
RANDO® phantom plans were created with one treatment field passing through 
each of the belly board and vacuum bag. Three treatment fields were used for 
each of the breast board and head extension plans.  The treatment fields were 
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placed to pass through varying amounts of the immobilisation device. During 
treatment, the fields for the belly board, vacuum bag and breast board also 
passed through the central region of the treatment couch where the ‘tennis string’ 
insert, covered with a Mylar sheet, was placed on the treatment couch. Figure 
3.14 shows one CT slice of the plans created for the RANDO® phantom on the 
breast board. 
 
(a)    
   
(b)  
 
Figure 3.14 Fields created for the RANDO® phantom on the breast board with 
only the phantom included in the body structure (a) and with the phantom and the 
immobilisation device included in the body structure (b). 
 
Dose reference points were selected in regions of the phantom where the beam 
had only passed through the immobilisation device and tissue equivalent 
sections of the phantom (i.e. not in or beyond lung or bone regions). One TLD 
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plug was selected for the belly board and vacuum bag plans, three for the head 
extension plans and four for the breast board plans. For the head extension and 
breast board plans, the plugs were selected to be behind different sections of the 
immobilisation device.  
 
3.3 Results and Discussion 
3.3.1 Errors and Uncertainties 
 
The uncertainty of the experimental measurements using the slab phantom with 
an ionisation chamber was estimated to have a 95% confidence interval of ±2% 
using the method described by Gregory et al (2005). 
 
The accuracy of the experimental measurements using the anthropomorphic 
phantom with TLD chips was estimated to be 3% as the TLD chips were 
positioned in areas of low dose gradient (Dunscombe et al 1996).  This value is 
consistent with the uncertainty calculated using the method described by Gregory 
et al (2005). 
 
Based on the documentation describing the accuracy of the Eclipse™ TPS PBC 
algorithm (Varian Medical Systems 2003b), the uncertainty for calculations using 
the slab phantom with no immobilisation device was taken to be 1% and the 
uncertainty for calculations for all other set ups was taken to be 2.5% (by 
averaging the quoted uncertainty of 2-3% for a typical clinical set up). 
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3.3.2 Slab Phantom 
3.3.2.1 No Immobilisation Device 
 
Table 3.1 shows the difference obtained between the measured and calculated 
dose for the slab phantom when no immobilisation device was present.  These 
results indicate that the measurements agree to within 0.5% of the dose 
calculated by Eclipse™. 
 
All of these results are within the 2% tolerance level and the 1% accuracy quoted 
in the Vision™ Calculation Algorithms (Varian Medical Systems 2003b) manual 
for rectangular fields, photon beam reconstruction model (homogeneous water 
equivalent material, no surface curvature). 
 
Field Size (cm2) % Difference 
5 x 5 -0.5 
10 x 10 -0.2 
20 x 20 0.4 
 
Table 3.1 The percentage difference between the measured and calculated dose 
for the slab phantom, no immobilisation device set up.  The uncertainty for the 
measured dose is estimated to be ±2% and for the calculated dose ±1%. 
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3.3.2.2 With Immobilisation Device 
 
Table 3.2 and Table 3.3 show the results for the slab phantom when an 
immobilisation device was present, with and without the immobilisation device 
included in the body structure.   
 
Immobilisation 
Device Region 
Field Size 
(cm2) 
% Difference 
Device Not 
Contoured 
% Difference 
Device 
Contoured 
Head Extension Grid 5 x 5 -0.6 -0.3 
Head Extension Grid 10 x 10 -0.3 -0.3 
Head Extension Grid 20 x 20 0.4 1.1 
Head Extension Shoulder 5 x 5 -2.8 -1.1 
Head Extension Shoulder 10 x 10 -2.0 -0.9 
Head Extension Shoulder 20 x 20 -1.1 0.1 
 
Table 3.2 The percentage difference between the measured and calculated dose 
for the slab phantom, with immobilisation device set up (Head Extension Board).  
The uncertainty for the measured dose is estimated to be ±2% and for the 
calculated dose ±2.5%. 
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Immobilisation 
Device 
Field Size         
(cm2) 
% Difference 
Device Not 
Contoured 
% Difference 
Device Contoured
Belly Board 5 x 5 -2.7 -1.6 
Belly Board 10 x 10 -1.5 -1.1 
Belly Board 20 x 20 -0.6 0.4 
Breast Board 5 x 5 -8.4 -1.3 
Breast Board 10 x 10 -7.1 -1.5 
Breast Board 20 x 20 -5.4 -0.6 
Vacuum Bag 5 x 5 -1.7 -1.5 
Vacuum Bag 10 x 10 -0.6 -0.8 
Vacuum Bag 20 x 20 0.1 0.4 
 
Table 3.3 The percentage difference between the measured and calculated dose 
for the slab phantom, with immobilisation device set up (Belly Board, Breast 
Board and Vacuum Bag).  The uncertainty for the measured dose is estimated to 
be ±2% and for the calculated dose ±2.5%. 
 
Device Not Contoured 
Any difference obtained when the immobilisation device is not included in the 
body structure is to some extent the result of the attenuation by the device in the 
beam path. All of the immobilisation devices used were designed so the areas 
through which fields are expected to pass will be as radiotranslucent as possible 
(i.e. resulting in minimal attenuation), while maintaining the strength and rigidity 
required for patient immobilisation.  As a result, the majority of the measurements 
when the immobilisation devices were not contoured were within the 2.5% 
tolerance level.  The main exception to this was for the breast board, where none 
of the results when the breast board was not included in the body structure were 
within the tolerance level, the maximum difference being 8.4%.  These large 
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differences resulted from the field passing through a central region of the breast 
board, consisting of a solid carbon fibre base support section (~1.0 cm thick) and 
the tilted back support region made of two thin sheets of carbon fibre (~0.2 cm 
thick) with a low density core (~1.5 cm thick).  
 
Although no standard tangential breast field would pass directly through the 
central region of the base support, posterior fields, such as those used to treat 
the axilla region, may pass through the base support either wholly or in part.  It is 
also possible that the breast board may be used for treatments not considered 
during its design, such as lung or spine treatments.  In these cases, the fields 
may also pass through a central section of the breast board. 
 
If a beam did pass through the central section of the breast board, ignoring the 
dosimetric effects of the device would result in a significant error in the dose 
calculation.  The dose calculation would also result in the absorbed dose to the 
target volume being not delivered to an accuracy of 5% or better as 
recommended by the ICRU (ICRU Report 24 1976).    
 
Applying a blanket transmission factor to correct the dose calculation would only 
be appropriate if the field passed wholly through the central section of the breast 
board.  However, an error in the dose calculation may still result if the 
transmission factor was only measured for a limited number of field sizes and 
shapes and not for the specific shape and size of field used for the patient 
treatment.   
 
The breast board is also designed to allow a flexible set up.  The angle of the 
tilted back support region can be varied relative to the base support and the 
transmission factor may vary with the change in angle between the base and 
tilted back support regions.  The variety of field shapes and sizes and flexibility in 
the set up of the breast board may result in the measurement of a large number 
of transmission factors being required, limitations in use of the breast board 
Page 87 of 169 
being applied or the acceptance of the uncertainty in the dose calculation for 
fields which passed through the base support region of the breast board. 
 
If a blanket transmission factor was applied when the field passed only in part 
through the base support of the breast board the dose calculation would result in 
the area beyond the back support being overestimated and the area not beyond 
the back support being underestimated. If the transmission factor was calculated 
using average transmission between the two sections of the board, due to the 
high attenuation by the back support region the dose calculation in neither of the 
areas would be within the desired accuracy for the dose calculation of better than 
2.5% (Van Dyk 1999).   
 
Applying a transmission factor may also not result in an accurate indication of the 
skin dose beyond the immobilisation device, which may be of clinical significance 
in some treatment scenarios. 
 
The use of transmission factors to correct the dose calculation is not ideal and 
can result in inaccuracies in the dose calculation.  A method such as 
incorporating the immobilisation devices used in the dose calculation, which 
would account for variations in the material and thickness of the immobilisation 
device and the resultant changes in dose distribution would be preferred. 
 
Device Contoured 
The vacuum bag point was behind a ~3.0 cm thick section of the vacuum bag 
and the belly board point was behind an ~8.0 cm thick section of the belly board, 
consisting of a carbon fibre shell filled with a low density core.  Based on the 
results from the studies investigating the effects of low density inhomogeneities, 
where large thickness of low density material are present, areas of electronic 
disequilibrium may occur and a reduction of dose immediately beyond the 
inhomogeneity due to a loss of scatter may result, particularly for smaller field 
sizes and higher energies (see Section 2.6.2).  Mackie et al (1985) noted that the 
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measured dose became closer to the calculated dose with increasing depth 
beyond the low density inhomogeneity, being consistent with the results being 
within tolerance levels at a depth of 5 cm in the phantom. 
 
For all of the primarily low density immobilisation devices (belly board, vacuum 
bag and head extension (shoulder region)), the percentage difference between 
the calculated and measured dose increased as the field size decreased. The 
increase in errors with reducing field size is consistent with the previously 
published studies investigating the dose behind low density inhomogeneities 
(Mackie et al 1985, Metcalfe et al 1993). 
 
For the breast board, the field passed through a large air gap, ~8.5 cm (between 
7 and 11 cm for the 20 x 20 cm2 field), between the base and shoulder support 
regions of board.  The published studies on air gaps did not investigate the dose 
behind air gaps as large as this and generally only applied the results obtained to 
the dose immediately beyond the air gap (see Section 2.6.1).  Chapter 4 
describes further investigations into the ability of the Eclipse™ TPS to accurately 
calculate the dose behind large air gaps.  In Chapter 5 a discussion of the results 
obtained for the breast board in this study considering the results from the air gap 
investigation is presented.  Despite any inaccuracies in the dose calculation by 
Eclipse™ beyond low density inhomogeneities and air gaps, including the 
immobilisation device in the body structure resulted in a significant improvement 
in the dose calculation accuracy. 
 
When the immobilisation devices were included in the body structure, all the 
results were within the tolerance level of 2.5%. 
 
As the Eclipse™ PBC algorithm when used with the ETAR method of 
inhomogeneity correction does not account for situations of electronic 
disequilibrium and changes in scatter conditions due to inhomogeneities, further 
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verification studies are required to confirm that the dose near the immobilisation 
device is calculated accurately.   
 
3.3.3 RANDO® Phantom 
3.3.3.1 No Immobilisation Device 
 
Table 3.4 shows the difference obtained between the measured and calculated 
dose for the RANDO® phantom when no immobilisation device was present.   
 
Field Description % Difference (Dose) 
6 MV behind Bone -1.9 
6 MV in Lung -2.2 
6 MV in Tissue -1.6 
 
Table 3.4 The percentage difference between the measured and calculated dose 
for the RANDO®  phantom, no immobilisation device set up.  The uncertainty for 
the measured dose is estimated to be ±3% and for the calculated dose ±2.5%. 
 
All of the results are within the 2.5% accuracy for the plan and treat steps 
required to fulfil the recommendations of the ICRU (ICRU Report 24 1976, Van 
Dyk 1999) and the 2-3% accuracy expected from Eclipse™.   
 
The results indicate that Eclipse™ can calculate the dose in a tissue equivalent 
material to within 1.6%, with an irregular surface and no inhomogeneities.  The 
larger difference obtained for the lung result is consistent with the previously 
published studies (Mackie et al 1985, Metcalfe et al 1993, du Plessis et al 2001, 
Engelsman et al 2001 and Carrasco et al 2004), where large errors within and 
Page 90 of 169 
beyond low dose inhomogeneities were observed for dose calculation algorithms 
utilising the ETAR method of inhomogeneity correction. 
 
3.3.3.2 With Immobilisation Device 
 
Table 3.5 shows the difference obtained between the measured and calculated 
dose for the RANDO® phantom when there was an immobilisation device 
present.   
 
Immobilisation 
Device Point 
% Difference 
Device Not 
Contoured 
% Difference 
Device Contoured
Head Extension 1 -2.4 -0.3 
Head Extension 2 -3.7 -2.2 
Head Extension 3 -3.8 -1.8 
Belly Board 1 -4.7 -2.1 
Breast Board 1 -7.7 0.5 
Breast Board 2 -3.6 -0.9 
Breast Board 3 -7.7 -2.5 
Breast Board 4 -2.1 -1.3 
Vacuum Bag 1 -2.5 0.8 
 
Table 3.5 The percentage difference between the measured and calculated dose 
for the RANDO®  phantom, with immobilisation device set up.  The uncertainty 
for the measured dose is estimated to be ±3% and for the calculated dose 
±2.5%. 
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Device Not Contoured 
When the immobilisation device was not included within the body structure, 
differences greater than the desired 2.5% were measured. Eclipse™ 
overestimates the dose in every case, reflecting the failure to adequately account 
for the attenuation of the immobilisation devices placed in the beam’s path. 
 
The largest difference (-7.7%) was obtained for breast board Points 1 and 3.  
Point 1 was within a laterally located field, where half of the field passed through 
the solid carbon fibre base of the breast board, a ~6.5 cm air gap and the tilted 
back support region of the breast board (made of two thin sheets of carbon fibre 
with a low density core).  The other half of the field passed through only the thin 
grid section of the breast board.  Point 3 within a centrally located field where the 
entire field passed through base and back support sections of the breast board 
and an ~8.5 cm air gap.  As both Points 1 and 3 were behind the base and back 
support of the breast board, the large dose difference obtained for those points 
reflects the neglected attenuation due to the immobilisation device.  
 
Breast board Point 1 was located within the same field as breast board Point 2, 
with Point 2 located behind a thin grid section of the breast board.  The location 
of the two points can be seen in Figure 3.14 (page 81).  Breast board Point 4 was 
located within a field that passed through only the thin grid section of the breast 
board.  Point 4 had the lowest difference of the breast board points of -2.1%.  
The difference obtained for Point 2 was larger (-3.6%) which may have been due 
to a reduction in scatter reaching the point from the section of the field behind the 
base and back support, where the primary component of the beam was reduced. 
 
For the head extension board, Points 1 and 2 were behind the carbon fibre grid 
section of the board and also behind the skull bone of the RANDO® phantom. 
Small air gaps, up to a few centimetres thick, were present between the grid 
section head extension board and head of the RANDO® phantom due to a thin 
plastic head rest supporting the phantom. The field incident on Point 2 
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intersected with the carbon fibre grid and the carbon fibre frame of the head 
extension board.  Head extension board Point 3 was behind the carbon fibre 
(with a low density core) shoulder support region of the board.  When the head 
extension board was not included in the dose calculation, the difference between 
the measured and calculated results was up to -3.8% (Point 3).   
 
The vacuum bag point was behind ~6 cm of vacuum bag and ~4 cm deep in the 
phantom.  The belly board point was behind ~7 cm of the belly board, in a section 
consisting of a carbon fibre shell and low density core and ~6 cm deep in the 
phantom.  When the immobilisation devices were not included in the dose 
calculation the difference between the measured and calculated results was        
-2.5% and -4.7% for the vacuum bag and belly board respectively.   
 
Device Contoured 
When the breast board was included in the dose calculation, all the results were 
within the clinical tolerance of 2.5%.  Significant improvements in the dose 
calculation were observed for the points positioned beyond the base support of 
the breast board (Points 1 and 3) when the device was included in the dose 
calculation.   
 
The largest difference obtained was for Point 3 (-2.5%) which was behind a large 
air gap and near the surface of the phantom (~3 cm depth), consistent with the 
results of studies which have found that the ETAR method of inhomogeneity 
correction overestimates the dose behind air gaps near the air/tissue interface 
(Wong et al 1992, Wong et al 1996, Shahine et al 1999).  These results are 
discussed further in Chapter 5, where the results obtained for the breast board in 
this study considering the results from the air gap investigation (Chapter 4) is 
presented. 
 
For the head extension board, when the board was included in the calculation the 
differences for all the head extension board points were within the clinical 
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tolerance of 2.5%. However, Eclipse™ still overestimated the dose in all cases.  
These results are consistent with the ETAR method overestimating the dose 
behind low density inhomogeneities (Mackie et al 1985, Metcalfe et al 1993, du 
Plessis et al 2001, Engelsman et al 2001, Carrasco et al 2004). 
 
When the vacuum bag and belly board were included in the dose calculation, the 
differences reduced to within the clinical tolerance, with Eclipse™  overestimating 
the dose to the belly board point (-2.1%) as expected due to the low density 
inhomogeneity.  Eclipse™ underestimated the dose to the vacuum bag point 
(+0.8%), which was not expected based on the results of previous studies.  It is 
possible that this magnitude of difference between the TLD measured dose and 
the Eclipse™ point dose was due to uncertainties induced by the volume where 
the TLDs were placed being in a region where the dose gradient was up to 2.5% 
and/or the reproducibility of the TLDs being up to 2%. 
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3.4 Conclusions 
 
While some of the dose calculations for when an immobilisation device was not 
included in the body structure were within tolerance levels, errors of up to 8.4% in 
dose calculation were obtained for beams passing through the base support 
region of the breast board.  An error of this magnitude does not fulfil the 
recommendations of the ICRU for the accuracy required for the plan and treat 
steps (ICRU Report 24 1976, Van Dyk 1999).  For this case it was concluded that 
due to the significant attenuation of the beam by the immobilisation device, 
ignoring the device in the dose calculation is not appropriate.  As a field may 
pass only in part through the attenuating part of the device, it was also concluded 
that the use of a blanket transmission factor was also not appropriate. 
 
When the immobilisation device was included in the body structure all of the 
results improved to be within the 2.5% tolerance level. Including the 
immobilisation device in the body structure was found to increase the dose 
calculation accuracy and fulfil the recommendations of the ICRU for the accuracy 
required for the plan and treat steps (ICRU Report 24 1976, Van Dyk 1999).  The 
results were also consistent with the 2-3% accuracy expected from Eclipse™ 
(Varian Medical Systems 2003b).   
Page 95 of 169 
4 Investigation into the dose behind Air Gaps 
 
When some immobilisation devices are used, large air gaps are created either 
within the immobilisation device or between the treatment couch and/or the 
immobilisation device and the patient.  Figure 4.1 illustrates some examples 
where a field passes through a large air gap prior to entering the patient when a 
breast board, head rest and knee rest are used to immobilise the patient during 
treatment. 
 
(a)   
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(b)  
 
(c)  
 
Figure 4.1 Examples of patient treatments where the field passes through a large 
air gap prior to entering the patient. (a) A posterior axilla field for a patient on a 
breast board; (b) a posterior oblique IMRT field to the parotid where the patient is 
positioned with a face mask on a head rest and PMMA board; and (c) a posterior 
field to the femur where the patient is positioned using a knee rest. 
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Previous studies into the effects of air cavities on radiotherapy dose distributions 
have focused on small air cavities (up to 5 cm thick) to represent air cavities 
within a patient’s body (Young and Kornelsen 1983, Beach et al 1987, Wong et al 
1992, Wong et al 1996, Kan et al 1998, Shahine et al 1999, Li et al 2000, du 
Plessis et al 2001, Ding et al 2004).  These studies investigated the dose at 
shallow depths behind the air gap up to 2 cm (Li et al 2000, Ding et al 2004) or 4 
cm (Wong et al 1992, Wong et al 1996, Shahine et al 1999). Researchers who 
investigated the ETAR method of inhomogeneity correction found that it can 
result in an overestimation of dose beyond small air cavities (Wong et al 1992, 
Wong et al 1996, Shahine et al 1999).  
 
This chapter describes the materials, methods and results obtained for the dose 
delivered beyond various thicknesses of slab air gaps up to 15 cm thick and for 
varying thickness of water equivalent material before the air gap.  The results 
were compared to Eclipse™ dose calculations for each set up.  The aim of the 
study was to determine the magnitude of any errors in the Eclipse™ dose 
calculation beyond large air gaps. 
 
4.1 Materials 
 
Two phantom arrangements were used to investigate the dose beyond air gaps.  
A water phantom was used to obtain relative depth dose data beyond the air 
gaps for each set up and a solid water slab phantom was used to measure the 
absolute dose at a specified depth beyond the air gap for each set up for 100 
MUs.  The absolute dose measurements were used to normalise the relative 
data.  An illustration of the experimental set ups for the two phantoms can be 
seen in Figure 4.2.  For both phantoms, the thickness of the RW3 water 
equivalent slabs and the air gap could be varied. 
Page 98 of 169 
 
(a) (b) 
 
Figure 4.2 Illustration of the experimental set up for the air gap experiments for 
the water phantom (a) and the water equivalent slab phantom (b). 
 
4.1.1 Water Phantom and Parallel Plate Ionisation Chamber 
 
To obtain ionisation data as a function of depth in water behind an air gap, a 
Type 2001 water tank, manufactured by Wellhöfer Dosimetrie (Scanditronix 
Wellhöfer, Germany), was used (see Figure 4.3).  The outer dimensions of the 
water tank were 675 x 645 x 560 mm3 (L x W x H) and held approximately 200 
litres of water.  It has a motorised carriage that can drive an attached dosimeter 
to a desired x, y, z position with an accuracy of ±0.5 mm.  During measurements, 
the ionisation chamber is attached to a software controlled CU500E 
microprocessor control unit which has a built in dual channel electrometer with 
reversible polarity and auto-ranging.  The Wellhöfer OmniPro-Accept (Version 
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6.4) software controlled the ionisation dosimeter position and recorded the 
measurements obtained. 
 
 
 
Figure 4.3 Wellhöfer blue water phantom (http://www.scanditronix-
Wellhöfer.com/fileadmin/pdf/products/Relative_Dosimetry/Blue_Phantom.pdf) 
 
To create an air gap above the water surface, two Perspex strips, positioned 
approximately 25 cm apart, with their ends attached to opposite sides of the 
water tank, were used to support RW3 water equivalent slabs above the water 
surface.   The water equivalent RW3 slabs are illustrated in Figure 3.2 (page 65). 
 
An NACP01 parallel plate ionisation chamber (Scanditronix Wellhöfer, Germany) 
 was used to conduct the experimental depth dose measurements in the 
Wellhöfer water tank.  It has a graphite window 0.5 mm thick, an electrode 
spacing of 2 mm, a collecting electrode diameter of 10 mm and a guard ring 
width of 3 mm.  It is encased in a PMMA waterproof housing which has a 0.1 mm 
thick Mylar window in front of the entrance window of the chamber. The NACP01 
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chamber complies with the recommendations for relative dosimetry 
measurements of photon beams (IAEA TRS 398 2000).  
 
The effective point of measurement was taken to be on the inner surface of the 
entrance window (IAEA TRS 398 2000) and a correction for this was applied 
during the set up. Measurements were conducted in the continuous scanning 
mode with the bias set to -300 V.  The scans began at a depth of at least 15 cm 
in the water phantom and scanned towards the water surface to reduce the 
influence of meniscus formation when the detector is close to the water surface 
(IAEA TRS 381 1997). 
 
While parallel plate ionisation chambers are recommended for depth ionisation 
curves in high energy photon beams due to (i) their good resolution in the 
direction parallel to the radiation beam axis and (ii) their well defined effective 
point of measurement (IAEA TRS 381 1997, IAEA TRS 398 2000), it should be 
noted that several papers have reported an over response of parallel plate 
chambers in the build up region (Velkley et al 1975, Nilsson and Montelius 1986, 
Gerbi and Khan 1990, Rawlinson et al 1992). The magnitude of the over 
response decreases as the depth approaches the depth of dose maximum 
(Velkley et al 1975). 
 
Velkley et al (1975) proposed a method to correct parallel plate chamber 
measurements in the build up region. However Nilsson and Montelius (1986) and 
Gerbi and Khan (1990) found that the technique could lead to significant errors.  
Rawlinson et al (1992) proposed guidelines for assessing a parallel plate 
chamber’s suitability for build up region measurements in high energy photon 
beams, based on the wall diameter and electrode spacing of the chamber.  Using 
this method it was estimated that the NACP01 chamber would overestimate the 
dose at the surface by approximately 3%.  But it was noted that this (and all other 
published correction methods) do not apply under situations of extreme electron 
contamination (Rawlinson et al 1992). 
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As no simple or accurate correction method for dose measurements with parallel 
plate chambers in the build up region has been developed (IAEA TRS 381 1997) 
and it is expected that there would be significant electron contamination from the 
material present before the air gap, resulting in the published methods being not 
applicable, no corrections were applied to the results in the build up region when 
using the NACP01 chamber throughout this study.  The overestimation of dose 
predicted is not expected to obscure the major features observed in this study. 
 
Extrapolation chambers are the preferred device for measuring dose in the build 
up region (Velkley et al 1975, Gerbi and Khan 1990, IAEA TRS 381 1997, IAEA 
TRS 398 2000) however one was not available for use in these experiments.  
 
4.1.2 Water Equivalent Slab Phantom and Cylindrical Ion 
Chamber 
 
The slab phantom was used to obtain an absolute dose measurement for each 
experimental set up.  The slab phantom was the same as was used in the 
investigation into the dose beyond immobilisation devices.  It consisted of CTG 
solid water® slabs (see Figure 3.1 (page 65)) and RW3 water equivalent slabs 
(see Figure 3.2 (page 65)) stacked to create a phantom with dimensions 12 x 30 
x 30 cm3 as described in Section 3.1.1.1.  A schematic diagram of the slab 
phantom is shown in Figure 3.3 (page 66).  The centre of the ionisation chamber 
cavity was located at a depth of 5 cm. To create an air gap, RW3 water 
equivalent slabs were supported above the slab phantom using expanded 
polystyrene foam blocks at the edge of the phantom. 
 
The dosimetry system used with the slab phantom was the NE Technology Ltd, 
model 2571 Farmer type cylindrical ionisation chamber and Keithley 35617 
electrometer with the bias set to -300 V, as described in Section 3.1.3.1.  The 
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reference point of the chamber (central axis at the centre of the cavity volume) 
was set to the measurement depth (IAEA TRS 398 2000). 
 
4.1.3 Transmission Measurements 
 
The NE2571 cylindrical ionisation chamber and Keithley electrometer for the slab 
phantom measurements were also used to measure transmission through 
various thicknesses of RW3 slabs. 
 
4.2 Methods 
4.2.1 Depth Dose beyond Air Gaps 
4.2.1.1 Experimental Set Up 
 
The experimental set ups investigated were for air gaps of 1, 3, 5, 8, 10, 12.5 and 
15 cm thickness before the surface of the lower section of the phantom produced 
by 0.2, 0.5, 1, 2, 3 and 4 cm thickness of water equivalent material placed above 
the air gap. 
 
Air gaps of up to 15 cm were investigated as the thickness of the air gap between 
the treatment couch/base of the breast board and the tilted back support region 
of the breast board are typically 10-12 cm for breast treatments utilising posterior 
axilla fields. Air gaps of small thickness were also investigated to identify any 
trends with increasing air gap thickness and for comparison with previously 
published studies.  
 
Measurements were conducted with up to several centimetres of water 
equivalent material before the air gap to simulate the various situations which 
may occur. With an example of an extreme case being where a posterior field 
through the breast board may pass through a solid or supporting section of the 
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treatment couch and the solid base section of the breast board before passing 
through a large air gap, through the back support of the breast board and then 
entering the patient. 
 
As the width and length dimensions of the air gap created by the breast board 
are much larger than the typical field sizes used for posterior axilla fields during 
breast treatments (typical size is an equivalent square of side 7-12 cm), slab air 
gaps larger than the field size were used throughout these experiments.  
 
4.2.1.2 Calculating the Dose using Eclipse™ (Treatment Planning) 
 
Phantom CT sets were created in the Eclipse™ TPS to simulate each set up.  
This was done by creating a three dimensional rectangular structure to simulate 
the water tank and creating slabs at various distances above the surface of the 
water tank structure. The density of both of the sections of the phantom was set 
to be the density of water (Hounsfield unit equal to 0).  Hounsfield units are 
based on the attenuation coefficient of the material and are normalised such that 
the Hounsfield unit for water equals 0 (Khan 2003).   
 
A plan was then created for each set up with one 6 MV photon beam produced 
by a Varian CLINAC 600 radiotherapy LINAC.  The field size was 10 x 10 cm2 
defined at the isocentre (100 cm from source) which was set at the surface of the 
phantom on the distal side of the air gap.  The plan was created so that 100 MUs 
were delivered for the field.  The dose calculation parameters in Eclipse™ were 
as described in Section 3.2. 
 
The Eclipse™ TPS was used to calculate central axis depth dose data (40 data 
points per cm) for each plan. The data was then exported to a Microsoft Excel 
spreadsheet for analysis.  
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4.2.1.3 Experimental Measurements (Treatment Delivery) 
 
Depth dose measurements were taken for each of the planned set ups using the 
Wellhöfer water phantom with the NACP01 parallel plate ionisation chamber.  
Measurements were obtained to a depth of at least 15 cm beyond the surface of 
the water phantom.  The resultant data were smoothed to remove noise from the 
readings using the least squares algorithm in the OmniPro-Accept software and 
then exported into a Microsoft Excel spreadsheet for analysis.  The Wellhöfer 
system measured 50 data points per centimetre. 
 
For each set up, the dose for 100 MUs to 5 cm depth beyond the air gap was 
measured in the slab phantom using the NE2571 cylindrical ionisation chamber.  
The relative depth dose data was then normalised so the dose at 5 cm depth 
equalled the measured dose in each case. 
 
The measured and Eclipse™ calculated depth dose data were then compared, 
with particular attention paid to the depth of dose maximum for each set up.   
 
4.2.2 Transmission Measurements 
 
To determine what proportion of the dose was the result of the primary beam, 
transmission measurements were obtained through water equivalent RW3 slabs 
under ‘narrow’ and ‘broad beam’ geometry conditions.   
 
Narrow beam geometry refers to an experimental set up where the beam is as 
small as possible but just large enough to cover the detector. The ionisation 
chamber is placed sufficiently far away from the attenuator to ensure that 
scattered photons reaching the detector are minimal and the measured beam is 
comprised only of the remaining primary (i.e. non-scattered) photons.  When 
broad beam geometry is used, primary and scattered photons may reach the 
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detector.  The difference between narrow and broad beam geometry is illustrated 
in Figure 4.4. 
 
 
 
Figure 4.4 Narrow and broad beam geometry (Bushberg et al 2002). 
 
The measurements were obtained with the LINAC gantry set to 180o and the 
RW3 slabs placed on the collimator housing to attenuate the beam.  Using a 
retort stand on the raised treatment couch, the cylindrical NE2571 ionisation 
chamber was positioned at 165 cm from the radiation source on the central axis 
of the beam.  A 6 MV 1.5 cm thick Perspex build up cap was placed on the 
ionisation chamber to ensure complete electronic equilibrium for the 
measurement.  The experimental set up is illustrated in Figure 4.5. 
 
For the narrow beam set up, the field size was selected to just cover the 
ionisation chamber and build up cap (5 x 4 cm2 field size defined at the 
isocentre).  For the broad beam configuration a 10 x 10 cm2 field was set at the 
isocentre.  A fixed number of MUs (200) were delivered through varying 
thickness of RW3 slabs (0-20 cm) and the reading on the Keithley electrometer 
with the bias voltage set to -300 V recorded.   
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Figure 4.5 Experimental set up for the transmission measurements. 
 
A transmission factor was determined for each thickness of water equivalent 
slabs using Equation 4.1. 
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Equation 4.1 
 
Where Mx,a,b is the measurement of dose obtained with x cm of water equivalent 
material in the beam path for field size a x b, and M0,a,b is the measurement 
obtained for the open set up (i.e. with no attenuating material present). 
 
The results were transferred into Microsoft Excel, a graph created and a best fit 
exponential trend line calculated.  Based on the equation obtained for the trend 
line, the linear attenuation coefficient was found using Equation 4.2.  
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Where μa,b is the linear attenuation coefficient. 
 
Equation 4.2 is based on Equation 4.3 (Bushberg et al 2002). 
 
x
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Equation 4.3 
 
Where No is the number of photons incident on the attenuating material, N is the 
number of photons transmitted through a thickness of material x without 
interaction and μ is the linear attenuation coefficient. 
 
Equation 4.3 is valid for a mono-energetic beam of photons.  Applying the 
measured results to this equation is based on the assumption that the 
attenuation coefficient for the RW3 slabs does not change markedly for 
megavoltage photons with absorber thickness over the range of thickness 
measured.  Only the results for up to 14 cm (approximately the first half value 
layer) were used to determine the attenuation coefficient to minimise any affect of 
its value changing with absorber thickness. 
 
4.2.3 Scatter Analysis 
 
The dose due to scatter from the water equivalent material before the air gap to 
the point of measurement for a given thickness of water equivalent material (x), 
thickness of air (t) and field size (a x b) at a specified depth (d) beyond the air 
gap is Dx,t,d,a,b,scatter.  This was calculated by subtracting the primary dose 
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component of the beam from the total measured dose for the range of air gaps 
set up using Equation 4.4. 
 
( )xbadbadtxscatterbadtx baeDDD ,,,,0,0,,,,,,,,, μ−×−=  
Equation 4.4 
 
Where the measured dose beyond the air gap for the set up is  Dx,t,d,a,b and the 
primary dose component remaining after the beam has been attenuated by the 
RW3 slabs is the product of D0,0,d,a,b and xbae ,μ− . Where D0,0,d,a,b is the measured 
dose for the open set up (0 cm thickness of water equivalent slabs above a 0 cm 
thickness air gap) and μa,b is the attenuation coefficient determined for field size a 
x b.  For the calculation the narrow beam attenuation coefficient determined for 
the smallest possible field size was used. 
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4.3 Results 
4.3.1 Errors and Uncertainties 
 
The uncertainty of the experimental measurements of the dose beyond an air 
gap using the combination of the results from the slab and water phantoms with 
an ionisation chamber was estimated to have a 95% confidence interval of ±2% 
using the method described by Gregory et al (2005). The uncertainty in the 
calculation of the dose due to scatter from the water equivalent material before 
the air gap based on the experimental measurements was estimated to be 
±2.5%. 
 
Based on the documentation describing the accuracy of the Eclipse™ TPS PBC 
algorithm (Varian Medical Systems 2003b), the uncertainty in the dose 
calculations was estimated to be 2.5% (by averaging the quoted uncertainty for a 
typical clinical set up of 2-3%). 
 
4.3.2 Depth Dose Data 
 
A representative set of depth dose data (for 0.5, 2.0 and 4.0 cm thickness of 
water equivalent slabs positioned before 1, 5, 10 and 15 cm air gaps) are shown 
in Figure 4.6, Figure 4.7 and Figure 4.8. Data to a depth of 5 cm is shown where 
the 0 depth position is at the surface of the water phantom, on the distal side of 
the air gap.  The measured and Eclipse™ calculated data are shown on the same 
graph.  For a given thickness of water equivalent material before the air gap, 
Eclipse™ calculated the dose behind the air gap to be equivalent for each air gap 
size. Thus, only one curve is shown for the Eclipse™ calculated data and is 
labelled, for example “0.5 W x cm Air (Eclipse)” for 0.5 cm of water equivalent 
material for an air gap of thickness x cm.  All of the results are for a 6 MV beam 
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with a 10 x 10 cm2 field set at the surface of the water phantom which was 
positioned 100 cm from the radiation source. 
 
Table 4.1, Table 4.2 and Table 4.3 show the measured dose for the depths of 0, 
1, 5, 10, and 15 cm beyond the air gap for 0.5, 2.0 and 4.0 cm of water 
equivalent material before the air gap respectively. The percentage difference of 
the measured dose from the Eclipse™ calculated results is also shown. 
 
The measured and Eclipse™ calculated data to a depth of 5 cm for all 
combinations of air gap and water equivalent slabs before the air gap thickness 
is presented in Appendix 7.3.  Data was collected to a depth of 15 cm but the 
data to a reduced depth is shown in the graphs so the significant effects can be 
observed. 
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Figure 4.6 Measured and Eclipse™ depth dose data beyond various air gaps for 
0.5 cm water equivalent material before the air gap.  The uncertainty for the 
measured dose is estimated to be ±2% and for the calculated dose ±2.5%. 
 0.5 cm Water Equivalent Material before Air Gap 
 Air Gap (cm) 
 1 5 10 15 
Depth 
(cm) Dose (cGy) % Diff Dose (cGy) % Diff Dose (cGy) % Diff Dose (cGy) % Diff 
0 95.2 15.0 91.8 11.8 80.0 -1.1 71.2 -13.7 
1 100.7 -0.3 100.1 -0.9 99.5 -1.5 99.0 -2.0 
5 84.3 -0.4 84.1 -0.7 83.9 -1.0 83.8 -1.1 
10 64.9 -1.7 64.6 -2.2 64.6 -2.3 64.6 -2.2 
15 49.3 -0.7 49.0 -1.3 48.9 -1.5 49.2 -1.0 
 
Table 4.1 Measured depth dose data and percentage variation of measured 
depth dose data from Eclipse™ calculated results beyond various air gaps for 0.5 
cm water equivalent material before the air gap.  The uncertainty for the 
measured dose is estimated to be ±2% and for the calculated dose ±2.5%.  
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Figure 4.7 Measured and Eclipse™ depth dose data beyond various air gaps for 
2.0 cm water equivalent material before the air gap.  The uncertainty for the 
measured dose is estimated to be ±2% and for the calculated dose ±2.5%. 
 2.0 cm Water Equivalent Material before Air Gap 
 Air Gap (cm) 
 1 5 10 15 
Depth 
(cm) Dose (cGy) % Diff Dose (cGy) % Diff Dose (cGy) % Diff Dose (cGy) % Diff 
0 102.1 -0.6 95.5 -6.8 79.4 -22.7 67.9 -34.1 
1 97.0 -1.5 95.4 -2.8 93.5 -4.4 91.8 -5.5 
5 79.8 -1.7 79.1 -2.1 78.2 -3.1 78.0 -3.0 
10 60.9 -2.2 60.5 -2.5 60.1 -2.9 59.8 -3.0 
15 46.1 -2.5 45.9 -2.3 45.5 -2.7 45.6 -2.0 
 
Table 4.2 Measured depth dose data and percentage variation of measured 
depth dose data from Eclipse™ calculated results beyond various air gaps for 2.0 
cm water equivalent material before the air gap.  The uncertainty for the 
measured dose is estimated to be ±2% and for the calculated dose ±2.5%. 
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Figure 4.8 Measured and Eclipse™ depth dose data beyond various air gaps for 
4.0 cm water equivalent material before the air gap.  The uncertainty for the 
measured dose is estimated to be ±2% and for the calculated dose ±2.5%. 
 4.0 cm Water Equivalent Material before Air Gap 
 Air Gap (cm) 
 1 5 10 15 
Depth 
(cm) Dose (cGy) % Diff Dose (cGy) % Diff Dose (cGy) % Diff Dose (cGy) % Diff 
0 96.3 -0.3 89.0 -7.8 73.4 -23.2 61.9 -35.2 
1 91.2 -1.3 88.5 -3.8 86.0 -5.8 84.4 -7.6 
5 74.2 -0.7 72.8 -2.8 71.8 -4.1 71.1 -4.7 
10 56.2 -1.6 55.6 -3.2 55.0 -4.1 54.9 -4.0 
15 42.3 -2.0 42.1 -3.1 41.8 -3.5 41.7 -3.2 
 
Table 4.3 Measured depth dose data and percentage variation of measured 
depth dose data from Eclipse™ calculated results beyond various air gaps for 4.0 
cm water equivalent material before the air gap.  The uncertainty for the 
measured dose is estimated to be ±2% and for the calculated dose ±2.5%. 
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4.3.2.1 Depth of Dose Maximum 
 
The depth of the dose maximum determined experimentally and calculated by 
Eclipse™ for the various set ups are shown in Table 4.4 and Table 4.5.   
 
Air Gap (cm) Material 
before 
Air Gap 
(cm) 1 3 5 8 10 12.5 15 
0.2 1.12 1.13 1.18 1.17 1.12 1.26 1.30 
0.5 0.86 0.86 0.84 0.91 0.94 1.05 1.13 
1 0 0.34 0.56 0.87 0.84 0.94 1.13 
2 0 0 0.41 0.72 0.83 0.93 1.05 
3 0 0 0.44 0.72 0.80 0.88 1.05 
4 0 0 0.36 0.72 0.84 0.92 1.05 
 
Table 4.4 Depth of dose maximum (cm) determined experimentally.  The depth 
of dose maximum measured for an open field was 1.34 cm.  The uncertainty is 
estimated to be ±0.2 cm. 
Air Gap (cm) Material 
before 
Air Gap 
(cm) 1 3 5 8 10 12.5 15 
0.2 0.78 0.75 0.76 0.75 0.75 0.75 0.78 
0.5 0.53 0.48 0.50 0.48 0.50 0.53 0.50 
1 0 0 0 0 0 0 0 
2 0 0 0 0 0 0 0 
3 0 0 0 0 0 0 0 
4 0 0 0 0 0 0 0 
 
Table 4.5 Depth of dose maximum (cm) calculated by Eclipse™.  The depth of 
dose maximum calculated by Eclipse™ for an open field was 1.32 cm. 
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4.3.3 Transmission Results 
 
The results for the attenuation measurements through the RW3 water equivalent 
slabs are shown in Appendix 7.4.  A good fit was obtained using an exponential 
curve (R2=0.9998) for both the narrow beam and 10 x 10 cm2 field size set ups.  
The attenuation coefficient obtained was similar for both the narrow beam and 10 
x 10 cm2 field size cases, being 0.502 and 0.500 respectively.  The narrow beam 
results were used during the scatter analysis in the following section. 
 
4.3.4 Scatter Analysis 
 
The results of the scatter analysis show the dose due to scattered radiation 
created by the water equivalent material before the air gap reaching beyond the 
air gap.   The results to a depth of 2 cm for 0.5, 2.0 and 4.0 cm material before 
the air gap for 1, 5, 10 and 15 cm air gaps are shown in Figure 4.9, Figure 4.10 
and Figure 4.11.  The results for all the set ups to a depth of 5 cm can be found 
in Appendix 7.5. 
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Figure 4.9 The total dose due to scatter from the 0.5 cm water equivalent 
material before the air gap. The uncertainty in the dose calculation is estimated 
to be ±2.5%. 
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Figure 4.10 The total dose due to scatter from the 2.0 cm water equivalent 
material before the air gap. The uncertainty in the dose calculation is estimated 
to be ±2.5%. 
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Figure 4.11 The total dose due to scatter from the 4.0 cm water equivalent 
material before the air gap. The uncertainty in the dose calculation is estimated 
to be ±2.5%. 
 
4.4 Discussion 
4.4.1 Surface Dose and Dose in the Build Up Region 
 
It can be seen in Figure 4.6, Figure 4.7 and Figure 4.8 that for a given thickness 
of water equivalent material before the air gap, as the size of the air gap 
increases, the dose measured beyond the air gap decreases.  For 0.5 cm of 
material before the air gap, where electronic equilibrium is not established in the 
material before the air gap, Figure 4.6 shows that for all air gaps there is a region 
of dose build up beyond the air gap.  In Figure 4.7 and Figure 4.8, it can also be 
seen that there is a secondary region of dose build up beyond the air gap for air 
gaps greater than 1 cm thickness even when electronic equilibrium is established 
in the material before the air gap. 
 
The reduction in dose beyond the air gap is due to a reduction in scattered 
radiation, created in the material before the air gap, reaching the measurement 
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point beyond the air gap.  This occurs as some of the scattered radiation 
produced in the material before the air gap which would have reached the 
measurement point if no air gap was present, is now scattered away from the 
measurement point. The amount of scattered radiation that is ‘lost’ in this manner 
increases with increasing air gap thickness, as the distance between the source 
of the scattered radiation and the measurement point increases.  This is visible in 
the results of the scatter analysis shown in Figure 4.9, Figure 4.10 and Figure 
4.11. 
 
When the radiation enters the air gap, the amount of scattered radiation 
produced reduces and the range of the scattered electrons and photons 
increases.  These changes result in the loss of electronic equilibrium (if present).  
When the beam enters the phantom beyond the air gap, a secondary build up 
region is required to re-establish electronic equilibrium within the material beyond 
the air gap.  Eclipse™  does not predict the presence of a secondary build up 
region as the ETAR inhomogeneity correction method does not account for 
situations of electronic disequilibrium or changes in electron transport with 
inhomogeneities.  
 
In the 2 cm water equivalent material before a 1 cm air gap set up (Figure 4.7), 
the dose at the surface is larger than the dose for the 0.5 and 4 cm material 
before a 1 cm air gap (Figure 4.6 and Figure 4.8).  This is due to the SSD of the 
set up changing with the thickness of water equivalent material and air gap 
before the water phantom (which was set at 100 cm from the source).  Depth 
dose data is dependent on SSD which results in the higher dose at the surface 
for the 2 cm material before the air gap set up (Metcalfe et al 1997). 
 
In the measured depth dose data presented, the dose near the surface (at 
depths of 0 – 0.2 cm) appears to increase at the surface compared to a line 
which would be extrapolated to the surface from depths of ~1.0 cm.  This is 
particularly apparent in the first 0.1 cm of data.  This is attributed to the 
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overestimation of dose in the build up region by fixed separation parallel plate 
chambers which was not accounted for in the data (Velkley et al 1975, Nilsson 
and Montelius 1986, Gerbi and Khan 1990, Rawlinson et al 1992, IAEA TRS 381 
1997).  This effect may also be due to the effective point of measurement for the 
NACP01 parallel plate ionisation chamber being 0.6mm beyond the surface of 
the ion chamber, i.e. on the inner surface of the entrance window (IAEA TRS 398 
2000).  When the chamber is positioned at depths less than 0.6mm, part of the 
chamber is above the water surface.  The build up of electron fluence will 
therefore start above the water surface within the entrance window and result in 
a higher than expected value at the surface being measured when compared to a 
surface dose obtained by extrapolation.  The thickness of material present in 
which a build up of electron fluence can occur is constant for depths less than 
0.6mm resulting in an approximately constant ionisation reading in this region.  It 
is also possible that this effect may be partially due the presence of a small 
amount of water remaining on the chamber (due to surface tension of the water) 
when taking the reading even though the position of the chamber surface was 
above the water surface.  Due to the small nature of these affects, they do not 
obscure the trends observed in this study. 
 
In Figure 4.6, the sharp points visible in the Eclipse™ depth dose data were 
attributed to the first stage of the dose calculation process only calculating the 
dose in five planes perpendicular to the beam and interpolating the results to 
obtain the dose for the other points.  This effect is only noticeable for Eclipse™ 
depth dose data where a build up region is predicted as where no build up region 
is predicted the results are close to being a straight line.  A build up region is 
predicted by Eclipse™ for set ups where the material before the air gap is less 
than or equal to 1 cm (see results in Appendix 7.3). 
 
The surface dose results obtained in this study are consistent with those 
obtained by Wong et al (1992), Shahine et al (1999) and Li et al (2000).  A 
comparison of the percentage error in surface dose calculation beyond air gaps 
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(using the ETAR inhomogeneity correction) from Wong et al (1992) to the results 
obtained in this study is shown in Table 4.6.  The decrease in surface dose with 
increasing air gap thickness can be seen in both sets of results, which was not 
accounted for by the dose calculation algorithms. The experiments by Wong et al 
(1992) were conducted using a Markus chamber, which, due to its smaller wall 
diameter, would be expected to exhibit a larger over-response in the build up 
region when compared to a NACP01 chamber (Rawlinson et al 1992).   The 
largest air gap thickness investigated by Wong et al (1992) was 4 cm resulting in 
a limited application of the results.  The current study has extended the results 
available to air gaps of up to 15 cm thick resulting in more flexible applications. 
 
 Percentage Error in Surface Dose 
Air Gap 
Thickness (cm) 
Wong et al 
(1992) Current Study 
1 +0.8 -0.3 
2 -1.8  
3 -6.9 -2.4 
4 -10.3  
5  -7.8 
 
Table 4.6 Comparison of surface dose results for 4 cm water equivalent material 
before various air gaps (6 MV, 10 x 10 cm2 field size, 100 cm SSD).   
 
The presence of a secondary build up region behind an air gap is consistent with 
the results of previous studies investigating the dose behind slab air gaps (Wong 
et al 1992, Shahine et al 1999, Li et al 2000, Ding et al 2004).   
 
The magnitude of the error in the dose calculation at the surface of the phantom 
beyond the air gap observed in this study is large (up to 35.2%).  Errors in the 
dose calculation of this magnitude are not in accordance with the 
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recommendation of the ICRU that the absorbed dose to the target volume should 
be delivered to an accuracy of 5% or better (ICRU Report 24 1976). 
 
When the Eclipse™  dose calculation algorithm is used with the ETAR 
inhomogeneity correction method, a significantly lower dose than expected may 
be delivered to a surface beyond a large air gap.  While this may be desirable if 
the target volume is not near the surface beyond the air gap, if the target volume 
is near the surface, an unacceptable reduction in dose may result.  
 
4.4.2 Depth of Dose Maximum 
 
The depth of the dose maximum determined experimentally and calculated by 
Eclipse™ for the various set ups are shown in Table 4.4 and Table 4.5.  Two 
trends can be seen in the measured results shown in Table 4.4: (i) when the 
thickness of the air gap increases, the depth of dose maximum increases 
towards that for an open beam (i.e. no attenuating material present); and (ii) 
when the thickness of material before the air gap increases, the depth of dose 
maximum moves towards the surface. 
 
Based on the scatter analysis (Figure 4.9, Figure 4.10 and Figure 4.11), as the 
thickness of the air gap increases, scatter created by the material before the air 
gap reaching the surface of the phantom beyond the air gap decreases.  As the 
amount of scattered radiation reaching the distal side of the air gap decreases, 
more depth is required to reach electronic equilibrium so the depth of dose 
maximum is further away from the surface (see Table 4.4).   As the air gap 
thickness increases, the loss of scattered radiation results in relative depth dose 
data beyond the air gap which is comparable to that for an open beam, with a 
similar depth of dose maximum, but with the magnitude of the dose measured 
reduced due to attenuation of the beam.  
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For a given air gap, as the thickness of water equivalent material before the air 
gap increases, the depth of dose maximum moves towards the surface (Table 
4.4).  The results are consistent with the partial establishment of electronic 
equilibrium (for the 0.2-1.0 cm cases) and the establishment of electronic 
equilibrium (for the 2.0+ cm cases) in the material before the air gap and 
electrons produced depositing dose on the distal side of the air gap.   
 
The measured depths of dose maximum from this study are comparable to those 
obtained by Wong et al (1992). A comparison of the results is shown in Table 
4.7. 
 
 Depth of Dose Maximum (cm) 
Air Gap 
Thickness (cm) 
Wong et al 
(1992) Current Study 
1 0.2 0 
2 0.2  
3 0.2 0 
4 0.4  
5  0.36 
 
Table 4.7 Comparison of surface dose results for 4 cm water equivalent material 
before various air gaps (6 MV, 10 x 10 cm2 field size, 100 cm SSD. 
 
4.4.3 Dose beyond the Depth of Dose Maximum 
 
For a larger thickness of material before the air gap (e.g. 2.0 cm and 4.0 cm) as 
the air gap increases, the reduction in dose behind the air gap continues beyond 
the re-establishment of electronic equilibrium (see Figure 4.7 and Figure 4.8).  
This is due to a reduction in scattered radiation reaching the measurement point.  
This effect increases with increasing air gap thickness as shown in the results of 
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the scatter analysis in Figure 4.10 and Figure 4.11.  Eclipse™  does not account 
for situations of electron disequilibrium or changes in electron transport with 
inhomogeneities. There are also limitations in the equivalent tissue air ratio 
inhomogeneity correction method when accounting for scattered photons.  As a 
result, Eclipse™ does not model the loss of scatter and hence the depth dose 
data calculated for all air gaps are similar to the dose for no air gap and the 
continuing reduction in dose is not predicted. This dose calculation error can 
result in under-dosing the patient due to Eclipse™ overestimating the dose.   
 
In Figure 4.9, Figure 4.10 and Figure 4.11, it can also be seen that at depths 
beyond dose maximum, the amount of dose from scattered radiation increases 
with increasing thickness of the material before the air gap. 
 
The failure of the ETAR inhomogeneity correction method to model the reduction 
of dose with depth after a large gap was noted by Wong et al (1992), attributing 
the discrepancy to scaling assumptions in the ETAR method.  The results were 
observed for 4 cm water equivalent material before a 4 cm slab air gap measured 
to a depth of ~3 cm behind the air gap where the ETAR method overestimated 
the dose by ~2.8% (6 MV, 5 x 5 cm2 field size). The result measured by Wong et 
al (1992) is comparable to the current 4 cm water equivalent material before a 5 
cm slab air gap where the ETAR method overestimated the dose by 2.7% at a 
depth of 3 cm (see results in Appendix 7.3).   The largest air gap investigated by 
Wong et al (1992) was 4 cm. The set up was considered an extreme case of an 
internal body cavity and the results were not investigated further.  
 
Page 124 of 169 
Munjal et al (2006) investigated the ability of the PLATO-SUNRISE TPS to 
calculate the dose for a field passing through a 12 mm PMMA board then an ~8 
cm air gap (perpendicular incidence).  The results were compared to the 
measured dose at the centre of a homogeneous phantom (~9 cm depth for 
perpendicular incidence).  When the TPS included the board and air gap in the 
dose calculation, the TPS overestimated the dose by up to 1.5% (6 MV, 10 x 10 
cm2 field size).  This result is comparable to the result obtained for the 1 cm 
water equivalent material before a 10 cm air gap and a measurement depth of 10 
cm where Eclipse™ overestimated the dose by 1.8%.  Based on these results, 
the overestimation of the dose by the TPS in the study by Munjal et al (2006) 
could be accounted for by the presence of the air gap between the PMMA board 
and the phantom.   
 
As this reduction in dose at depth is apparent for 1 - 2 cm thickness of solid water 
before the air gap, significant effects on treatment plans could result, for 
example, when a posterior axilla field passes through the treatment couch and 
then the ~1.0 cm solid carbon fibre base support of the breast board before 
passing through a large air gap.  Based on a set up with 2 cm water equivalent 
material before the air gap, a 10 cm air gap and a depth of 10 cm in the patient, 
Eclipse™ would overestimate the dose by 2.9% which exceeds the clinical 
tolerance of 2.5% (see Table 4.2).  
 
A significant dose reduction at depths beyond the dose maximum behind the air 
gap has been observed.  The magnitude of the error in the dose calculation at 
depths beyond the depth of dose maximum were not within the desired accuracy 
for the planning stage of better than 2.5% (Van Dyk 1999) for a large proportion 
of the experimental set ups.   Generally, if the thickness of water equivalent 
material before the air gap was larger than 2.0 cm and the air gap larger than 5 
cm the error in the dose calculation was not within tolerance levels to a depth of 
10 to 15 cm beyond the air gap. 
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4.5 Conclusions 
 
The study confirmed that the ETAR method of inhomogeneity correction results 
in significant errors in dose calculation beyond air gaps.  The method does not 
account for the loss of electronic equilibrium which occurs due to the air gap and 
as a result overestimates the dose beyond it. The results of the air gap 
investigation agree with the results of previous studies (Wong et al 1992, 
Shahine et al 1999, Li et al 2000, Ding et al 2004). The current study has 
extended the data from previous studies for air gaps up to 15 cm thick and to 
depths of up to 15 cm beyond the air gap.  
 
When the Eclipse™  dose calculation algorithm is used with the ETAR 
inhomogeneity correction method, a significantly lower dose than expected may 
be delivered to a surface beyond a large air gap and to target volumes at depths 
of up to 15 cm beyond a large air gap. 
 
The results of the current study may be used to apply a correction factor to the 
Eclipse™ calculated dose beyond air gaps. 
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5 Discussion of Combined Results and Conclusions 
5.1 Summary of Results 
 
The results of the investigation into the dosimetric effects of immobilisation 
devices showed that large errors may occur when the physical characteristics of 
these devices are not included in the body structure and hence not in the 
Eclipse™ dose calculation. The attenuating properties of the immobilisation 
devices should not be ignored.  The largest discrepancy between the Eclipse™ 
calculation and the measurements was obtained when a field passed through the 
solid carbon fibre base, an air gap and then the carbon fibre composite back 
support region of the breast board. For this case, Eclipse™ was found to 
overestimate the dose by up to 8.4% when the breast board was not included in 
the dose calculation (6 MV, 5 x 5 cm2 field size, slab phantom). 
 
When the immobilisation devices were included in the body structure, all of the 
measurements were within 2.5% of the Eclipse™ calculated dose.  Thus the 
results were all within the dose tolerances recommended by the ICRU (ICRU 
Report 24 1976) and other published studies describing the tolerances for the 
accuracy of dose calculations by a TPS (Van Dyk et al 1993, Fraas et al 1998, 
Venselaar et al 2001).  The results were also consistent with 2-3% accuracy 
specified by Eclipse™ for the PBC algorithm (Varian Medical Systems 2003b). 
 
The results of the air gap investigation agree with the results of previous studies 
for small air cavities (Wong et al 1992, Shahine et al 1999, Li et al 2000, Ding et 
al 2004) where a secondary region of dose build up beyond small air gaps was 
observed.  This secondary dose build up region is not predicted when the 
Eclipse™ PBC algorithm with the ETAR method of inhomogeneity correction is 
used to calculate the dose beyond an air gap for a 6 MV beam. 
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It was found that for a given thickness of water equivalent material located before 
the air gap, that as the size of the air gap increases, the dose measured beyond 
the air gap decreases (see Figure 4.6, Figure 4.7 and Figure 4.8). The measured 
depth of the dose maximum beyond the air gap also increases as the size of the 
air gap increases (see Table 4.4). It was also found that for a given air gap 
thickness, that as the thickness of water equivalent material before the air gap 
increases, the depth of dose maximum moves towards the surface (see Table 
4.4).  Eclipse™ does not predict these effects and overestimates the dose in the 
build up region. 
 
When there is a large thickness of water equivalent material located before the 
air gap (e.g. 2.0 cm or 4.0 cm (Figure 4.7 and Figure 4.8)), as the air gap 
increases, the overestimation of dose by Eclipse™ continues beyond the build up 
region. For the 2 cm material located before a 15 cm air gap case, Eclipse™ 
over-predicted the dose by 34% at the surface of the water phantom and by 3%, 
3% and 2% at depths of 5, 10 and 15 cm respectively (Table 4.2). 
 
5.2 Discussion of Combined Results 
 
The results of the air gap investigation can be used to interpret the results of the 
investigation into the dose behind immobilisation devices when air gaps were 
present.   
 
5.2.1 Slab Phantom with Ionisation Chamber 
 
The fields through the breast board on the water equivalent slab phantom passed 
through the carbon fibre/foam composite shoulder support before passing 
through an ~8.5 cm air gap then the solid carbon fibre base support.  Eclipse™ 
overestimated the dose by 1.3%, 1.5% and 0.6% for the 5 x 5 cm2, 10 x 10 cm2 
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and 20 x 20 cm2 fields respectively.  Based on the results closest to this scenario, 
of 0.2 cm water equivalent material before the air gap and an 8 cm air gap (see 
Appendix 7.3), it is expected that Eclipse™ would overestimate the dose by 0.4% 
for a 10 x 10 cm2 field.  This magnitude of error would be difficult to detect 
considering the experimental uncertainty, however, the larger error for the 
smaller field sizes is consistent with the results of Wong et al (1992) and Li et al 
(2000), who observed that the dose reduction behind the air cavity increased as 
the field size reduced. 
 
5.2.2 RANDO® Phantom with TLDs 
 
Breast board Point 1 was located ~7.0 cm beyond the surface of the RANDO® 
phantom, within a laterally located field where only half of the field passed 
through the solid carbon fibre base (~1.0 cm) and the carbon fibre composite 
back support regions of the breast board.  Point 1 was within the part of the field 
which passed through the base, then a ~6.5 cm air gap, then the back support.  
For this complex situation, when the breast board was included in the body 
structure, the measured dose was 0.5% above the Eclipse™ calculated dose.  
The air gap set up investigated which is most similar to this situation is the 1 cm 
water equivalent material before a 5 cm air gap.  Based on those results, the 
measured results for a depth of 7 cm are expected to be ~1.3% below the 
Eclipse™ calculated result (see Appendix 7.3  for results).  The measured result 
is consistent with the expected result from Eclipse™  considering the 2% 
uncertainty in the TLD measurement. 
 
Breast board Point 3 was located ~3.0 cm beyond the surface of the phantom, 
within a centrally located field where the entire field passed through the base, 
then an ~8.5 cm air gap, then the back support of the breast board before 
entering the RANDO® phantom.  When the breast board was included in the 
body structure, the result measured with the TLDs was 2.5% below the Eclipse™ 
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calculated result.   This is consistent with the results for the 1 cm water 
equivalent material before the air gap, 8 cm air gap, at 3 cm depth result where 
the measured result was 2.2% below the Eclipse™ calculated result (see 
Appendix 7.3 for results).  
 
Despite the inaccuracies in the dose calculation behind air gaps due to the 
deficiencies in the algorithm, the results obtained when the device and air gap 
were included in the dose calculation are more accurate than when the device 
was not included.   
 
5.3 Conclusions 
 
The current studies have investigated the ability of the Eclipse™ TPS (PBC 
algorithm, ETAR inhomogeneity correction) to calculate the dose beyond 
complex immobilisation devices and air gaps. 
 
With the increased use of conformal and IMRT techniques, treatments with many 
gantry angle settings are common and it is not unusual for treatment fields to 
pass through the treatment couch or immobilisation devices used.  While 
immobilisation devices and treatment couches are typically designed to have 
minimal affect on the radiation beam, it is not always possible to obtain the 
strength and rigidity required with perfectly radio-translucent materials.  Even low 
density materials may significantly alter the beam properties.  Reported effects of 
treatment couches and immobilisation devices include an increase in surface 
dose and beam attenuation.  Transmission factors can be used to account for 
attenuation in uniform devices but do not account for the increase in surface 
dose.  To account for attenuation of non-uniform thickness and density devices, 
the immobilisation devices and treatment couch may be modelled in the TPS. 
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It was found that not including objects external to the patient in the dose 
calculation (such as the treatment couch or immobilisation devices) can result in 
significant errors (up to 8.4%) in the dose calculation.  Typically the errors would 
result in under-dosing the patient due to the dose calculation not accounting for 
attenuation by the external object(s).  By including the external objects in the 
dose calculation, the errors can be reduced to within the clinical tolerance of 
2.5%. 
 
Large air gaps are created by some immobilisation devices which may result in 
dose calculation errors larger than the clinical tolerance.  A reduction in dose 
beyond the air gap occurs that is particularly significant near air/tissue interfaces.  
For a large thickness of material before the air gap and large air gaps, the 
reduction in dose beyond the air cavity can continue to a depth of 15 cm.  The 
reduction in dose beyond the air gap is due to a reduction in scattered radiation 
reaching the measurement point.  Eclipse™  does not predict this as it does not 
account for situations of electron disequilibrium or changes in electron transport 
with inhomogeneities and due to limitations in the equivalent tissue air ratio 
inhomogeneity correction method when accounting for scattered photons.  This 
dose calculation error can result in under-dosing the patient due to Eclipse™ 
overestimating the dose.   
 
The current study has extended the range of air gaps investigated from 5 cm to 
15 cm.  The depth beyond the air gap investigated has also been extended from 
4 cm to 15 cm.  The broad range of data obtained may be used to apply 
corrections to the dose calculation by Eclipse™  when an air gap is present. 
 
5.4 Areas Requiring Further Study 
 
If an immobilisation device and/or treatment couch is included in the dose 
calculation, the reproducibility of the position of the patient relative to the 
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immobilisation device and treatment couch needs to be confirmed. Previous 
studies, such as those reviewed by Verhey (1995) have determined the ability of 
immobilising systems to reposition skeletal anatomy.  Verhey (1995) noted that 
the results may not translate to the ability of the system to reposition the target 
volume.  The results may also not translate to the ability of the system to 
reposition the patient relative to the immobilisation device and treatment couch. 
No studies have been found describing the set up reproducibility of patient 
position relative to immobilisation devices.  To obtain the required reproducibility, 
additional fixation devices, such as lock bars to secure the immobilisation device 
to the treatment couch may be required. Additional treatment set up information 
may also be required to aid the reproducibility, such as the location of anatomical 
landmarks or set up tattoos on the patient relative to the immobilisation device. 
This may require a scale to be added to the immobilisation device. 
 
Anthropomorphic phantoms only allow detectors to be placed in set positions in 
each slice.  The measured dose distribution data is limited to those points.  Areas 
near the surface or at the interface near an inhomogeneity may not be able to be 
measured.  To determine the accuracy of the Eclipse™ PBC algorithm to 
calculate the dose behind immobilisation devices in regions of the patient 
adjacent to the immobilisation device and other areas of interest, a study based 
on a patient model (using patient CT scans) comparing the Eclipse™ results to 
those obtained using Monte Carlo could be conducted.  This type of study would 
provide further information regarding the dose calculation accuracy for a clinical 
set up in all areas of the patient and would allow dose volume histograms for 
areas of interest, such as critical structures and target volumes, to be compared. 
 
Monte Carlo calculations could be performed to determine the electron/photon 
components of the scattered radiation reaching beyond the air gap and to identify 
the cause of the reduction in dose at large depths beyond the air gap for some of 
the set ups.  Monte Carlo investigations could also be performed with a fixed 
SSD set up (to the surface of the material before the air gap) to eliminate affects 
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of the change in depth dose with changes in SSD.  Calculations using the 
Mayneord F factor (see Equation 7.5 (page151 )) to account for the effective 
change in SSD when the air gap thickness and thickness of material before the 
air gap is changed could also be performed but would not account for the change 
in scatter conditions (Khan 2003).   
 
Studies investigating the range of situations encountered in this study are not 
typically conducted during TPS commissioning.  As a result, dose calculation 
errors may be present which the TPS users are not aware of.  Similar studies to 
those conducted in this project should also be conducted on algorithms which 
have recently been released to determine the accuracy of the dose calculation 
when fields pass through immobilisation devices and air gaps. One example of a 
new algorithm which has not been investigated in this manner is the Eclipse™ 
Anisotropic Analytical Algorithm (AAA) which is used in the more recent versions 
of Eclipse™. 
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7.2 Eclipse™ Treatment Planning System 
7.2.1 Pencil Beam Convolution Dose Calculation Algorithm 
 
The Eclipse™ PBC algorithm for photon dose calculation is a correction based 
algorithm and is described as having two main phases.  The first is called the 
beam reconstruction model where the dose is reconstructed in a homogenous 
water equivalent medium (in the phantom geometry used for beam data 
acquisition) with field add-ons such as blocks, wedges, MLCs and compensators 
that modify the beam shape or modulate the beam intensity taken into account.  
As calculating the dose to the entire volume would be very time consuming, the 
convolution is used to calculate the dose in five planes perpendicular to the 
beam, and the dose for the other points in the volume is interpolated. The dose is 
then corrected to account for the distance along the central axis of the field from 
the focal spot to the patient’s skin in the treatment geometry. The second phase 
applies the patient model (based on the body structure contoured) to the 
calculation to account for the actual skin curvature and inhomogeneities (Varian 
Medical Systems 2003a).   
 
The convolution which is used to calculate the dose uses pencil beam scatter 
kernels, a conceptual picture of scatter kernels of beam, slab, pencil and point 
dimensions can be seen in Figure 7.1. 
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Figure 7.1 Scatter kernels of different dimension: (a) beam, (b) slab, (c) pencil 
and (d) point (Van Dyk 1999). 
 
These kernels can be interpreted as iso-contributions from upstream scattering 
points to a destination point of interest or as the energy spread from a scattering 
point to downstream voxels (Van Dyk 1999).  During the execution of the dose 
algorithm, the dose at a point is calculated by summing the effects from 
scattering elements.  The mathematical equation for a point kernel is given in 
Equation 7.1. 
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( ) ( ) '''),,;',','(',',',, dzdydxzyxzyxKzyxzyxD ∫∫∫Φ=  
Equation 7.1 
 
Where D(x,y,z) is the dose distribution, Φ is the primary source fluence incident 
upon the surface of the scatter kernel and K is the scatter kernel for the 
combination of scattering element (x’,y’,z’) and dose point (x,y,z) (Van Dyk 1999). 
 
For a point kernel, the equation is reduced to Equation 7.3 (Van Dyk 1999). 
 
( ) ( )∫∫Φ= ''),,;','(',',, dydxzyxyxKyxzyxD  
Equation 7.2 
 
In the approach known as the superposition principle, the kernels are assumed to 
vary throughout the irradiated volume and in heterogeneous tissue.  With this 
approach local changes in primary fluence and changes in the spread of energy 
due to local scattering can be accounted for.  If the scatter kernels are spatially 
invariant, such as for a mono-energetic non-divergent source incident on a 
homogeneous medium, then the dose integrals simplify to convolution integrals 
with the arguments of K being replaced with relative positions (x-x’, y-y’, z-z’).  
The advantage of this is that integrals can be calculated efficiently using fast 
Fourier transforms. When applied to a poly-energetic divergent beam incident on 
a heterogenous absorber some approximations are introduced to maintain the 
speed advantage, but at the expense of accuracy (Van Dyk 1999).  
 
The Eclipse™ PBC algorithm uses the latter method where the scatter kernels 
are considered to be spatially invariant.  The convolution integral used, shown in 
Equation 7.3, sums a number of pencil beams, each weighted with field intensity 
to obtain the total dose contribution.  
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''),','()''()','();,,( int dydxzyyxxKzyxPyxFFzyxD −−= ∫∫  
Equation 7.3 
 
Where D(x,y,z;F) is the dose at a point (x,y,z) for a field F, F(x’,y’) is the field 
intensity function (which describes the field shape, blocking and any intensity 
modulation in the field), Pint(x’,y’,z) is the intensity profile (normalised fluence of 
primary photons at depth z) and K(x-x’,y-y’,z) is the pencil beam kernel (Varian 
Medical Systems 2003b).   
 
This equation is used to compute the dose on the planes perpendicular to the 
beam at the standard depths.  The dose at points between the standard depths is 
interpolated along the fanlines of the beam, involving the calculation of: 
 
• the field intensity function, 
• the position of the effective axis (the fanline crossing the horizontal plane 
at a depth of 10 cm where the dose reaches its maximum value),  
• the size of the equivalent square field (determined to be the square field 
whose dose at a depth of 10 cm in the field centre equals the maximum 
dose at a depth of 10 cm on the effective axis for the irregular field),  
• the depth dose (of the irregular field along the effective field axis, Da(z;F)) 
and 
• the off axis ratio (P(x,y,z;F), computed by interpolation along the fan lines)  
(Varian Medical Systems 2003b).   
 
The absorbed dose is then calculated in the water equivalent medium using 
Equation 7.4. 
 
);,,();();,,( FzyxPFzDFzyxD a ×=  
Equation 7.4 
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The dose is then translated to account for any difference in the distance of the 
field central axis to the surface of the water equivalent material geometry 
compared to the patient geometry.  This is done by adjusting the equivalent field 
size where the field central axis intersects with the body structure, adjusting the 
depth dose values (using the Mayneord F factor and a tissue air ratio (TAR) 
correction) and applying an inverse square law correction (Varian Medical 
Systems 2003b).   
 
The Mayneord F factor is an approximate method for converting percentage 
depth dose data from a standard SSD set up to an actual SSD for the patient set 
up.  It is based on the inverse square law, without considering changes in 
scattering as the SSD is changed (Khan 2003). The formula for the Mayneord F 
factor given in Equation 7.5 . 
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Equation 7.5 
 
Where f1 is the initial SSD, f2 is the new SSD, dm is the depth of dose maximum 
and d is the depth of the point of interest. 
 
The TAR is defined as the ratio of the dose (Dd) at a given point in a phantom to 
the dose in free space (Dfs) at the same point (Khan 2003).  An illustration of the 
set ups used to determine a TAR can be found in Figure 7.2. 
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Figure 7.2 An illustration of the set ups used to determine a tissue air ratio (Khan 
2003). 
 
For a given beam quality, the TAR depends on the depth d and the field size rd at 
that depth.  TARs are independent of the source to surface distance. The formula 
defining TAR is given in Equation 7.6. 
 
fs
d
d D
DrdTAR =),(  
Equation 7.6 
 
The patient model determines how the skin curvature and tissue inhomogeneities 
are dealt with when applying the dose distribution which was calculated in the 
water equivalent material to the patient anatomy.  The patient model calculation 
is completed using Equation 7.7. 
 
inhoa CCFzyxPFzDFzyxD ×××= );,,();();,,(  
Equation 7.7 
 
Where Co is the correction factor for skin obliquity and Cinh is the correction factor 
for tissue inhomogeneities (Varian Medical Systems 2003b). 
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The skin obliquity correction factor accounts for patient skin curvature and is 
calculated along diverging fanlines between the calculation and focus points 
using the inverse square law and the TAR/TMR ratio.  The TMR is the tissue 
maximum ratio, which is the ratio of the dose at a given point in a phantom ( dD ) 
to the dose at the same point at a fixed reference depth (
ot
D ), when the 
reference depth (t0) is the depth of maximum dose (Khan 2003). The formula 
defining TMR is given in Equation 7.8. 
 
ot
d
d D
DrdTMR =),(  
Equation 7.8 
 
An illustration of the set ups used to determine a TMR can be found in Figure 
7.3. 
 
 
Figure 7.3 An illustration of the set ups used to determine a tissue maximum ratio 
(Khan 2003). 
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7.2.2 The Equivalent Tissue Air Ratio Inhomogeneity Correction 
Method 
 
The Eclipse™ External Beam Planning TPS version 6.5 has the capability to 
conduct inhomogeneity corrections using the generalised Batho power law, the 
modified Batho power law and the ETAR method (Varian Medical Systems 
2003b).  The method of inhomogeneity correction used throughout this project 
was the ETAR method, which was introduced by Sontag and Cunningham in the 
late 1970s (Sontag and Cunningham 1977, Sontag and Cunningham 1978).  A 
summary of the method is given below. 
 
According to the density scaling theorem, the TAR in a field of radius, r, at a 
depth, d, in a material of uniform density (ρ) relative to water, is equal to TAR(ρd, 
ρr), i.e. the TAR in a unit density medium for field size ρr and depth ρd. The 
inhomogeneity correction factor (ICF) for an homogeneous, water like medium 
with non-unit density is defined in Equation 7.9. 
 
( )
( )rdTAR
rdTARICF
,
,ρρ=  
Equation 7.9 
 
And the inhomogeneity correction factor for heterogeneous geometries is given 
in Equation 7.10. 
 
( )
( )rdTAR
rdTARICF
,
~,'=  
Equation 7.10 
 
Where d’ and r~ are the effective values of d and r respectively for the radiation 
value being used. d’ is derived by averaging CT values along primary photon ray 
paths and the effective beam radius is given by Equation 7.11 and Equation 7.12. 
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ρ~~ ⋅= rr  
Equation 7.11 
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Equation 7.12 
 
Where ρ~  is the average ‘weighted relative electron’ density, ρijk is the relative 
electron density of a pixel in the CT image and Wijk is a weighting factor 
proportional to an element’s contribution to the scattered radiation arriving at the 
point of calculation (Varian Medical Systems 2003b). 
 
The weighting factors depend on many conditions, such as the surrounding 
material and location of each point.  A different set of weighting factors is 
required for each point of calculation. The weighting factor is generally largest for 
voxels closest to the point of calculation. The summation is over the whole of the 
irradiated volume with the indices i, j and k referring to the X, Y, Z coordinate 
system (AAPM Report no. 85 2004, Varian Medical Systems 2003b). 
 
When this algorithm was developed, summations over the entire irradiated 
volume were deemed impractical for clinical use due to excessive computer 
memory requirements and calculation times. This resulted in the development of 
an approximation procedure which significantly reduces calculation time where 
the summation over the volume is reduced to a summation over a plane (CT 
slice), assuming that Wk is constant with respect to X and Y and only a function 
of Z. Wk then represents the relative importance of the kth slice contribution to the 
scatter dose at the point of calculation and Wij represents the relative importance 
as a function of X and Y positions within the effective scattering slice.  The total 
weighting factor is then approximated by Equation 7.13. 
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ijkijk WWW ⋅=  
Equation 7.13 
 
The summation equation can then be given by Equation 7.14 and Equation 7.15. 
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Equation 7.15 
 
Where the calculation of ijρ~  results in the reduction of the density data over the 
volume into an effective slice with respect to photon scattering (AAPM Report no. 
85 2004).  
 
This effective slice is assumed to be at a position Zeff away from the plane 
containing the point of calculation. Zeff represents the mean position from which 
the scatter originates, assuming that the material between the effective scatter 
slice and the calculation plane is water. Zeff can be calculated by Equation 7.16. 
 
∑
∑
=
k
k
k
kk
eff W
WZ
Z  
Equation 7.16 
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Where the summation is over the slices irradiated and Zk is the distance from the 
plane of calculation to the kth slice.  The coalescing CT slices converts a 3D 
calculation into what is called a 2.5 dimensional calculation (AAPM Report no. 85 
2004). A schematic diagram illustrating the conversion of the CT slices into an 
effective slice is shown in Figure 7.4. 
 
 
 
Figure 7.4 A schematic illustration of coalescing six CT slices into an effective CT 
slice (Sontag and Cunningham 1978). 
 
The weighting factors are determined by the difference of two scatter air ratios 
(SARs) (Varian Medical Systems 2003b).  SARs are used when calculating the 
scattered dose in a medium.  It is defined as the ratio of the scattered dose at a 
given point in the phantom to the dose in free space at the same point. Like 
TARs, SARs are independent of SSD but depends on beam energy, depth and 
field size (Khan 2003).  As the scattered dose at a point in a phantom is equal to 
the total dose less the primary dose at the point, they can be calculated using 
Equation 7.17. 
 
)0,(),(),( dTARrdTARrdSAR dd −=  
Equation 7.17 
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Where TAR(d,0) is the TAR for a 0x0 cm2 field, which represents the primary 
component of the beam (Khan 2003). 
 
The weighting factors, Wk, are then calculated using Equation 7.18. 
 
),(),( 12 rdSARrdSARW refrefk −=  
Equation 7.18 
 
Where r1 and r2 are the radii of equivalent circular beams and dref is the reference 
depth of 10 cm.  The scaled beam radius can then be obtained from Equation 
7.11 using Equation 7.19. 
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The Wij factors must be calculated for each point separately.  Some Wij factors 
are pre-calculated in the configuration (Varian Medical Systems 2003b). 
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7.3  Measured and Eclipse™ Air Gap Depth Dose Data 
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(a) Experimentally determined data 
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(b) Eclipse™ calculated data 
Figure 7.5 Depth dose data behind various air gaps, for 0.2 cm water equivalent 
material before the air gap, experimentally determined (a) and Eclipse™ 
calculated (b) results.  The uncertainty for the measured dose is estimated to be 
±2% and for the calculated dose ±2.5%. 
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Depth Dose behind Air Gap
0.5 cm Water Equivalent Slabs before Air Gap
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(a) Experimentally determined data 
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(b) Eclipse™ calculated data 
 
Figure 7.6 Depth dose data behind various air gaps, for 0.5 cm water equivalent 
material before the air gap, experimentally determined (a) and Eclipse™ 
calculated (b) results.  The uncertainty for the measured dose is estimated to be 
±2% and for the calculated dose ±2.5%. 
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Depth Dose behind Air Gap
1.0 cm Water Equivalent Slabs before Air Gap
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(a) Experimentally determined data 
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(b) Eclipse™ calculated data 
 
Figure 7.7 Depth dose data behind various air gaps, for 1.0 cm water equivalent 
material before the air gap, experimentally determined (a) and Eclipse™ 
calculated (b) results.  The uncertainty for the measured dose is estimated to be 
±2% and for the calculated dose ±2.5%. 
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Depth Dose behind Air Gap
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(a) Experimentally determined data 
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(b) Eclipse™ calculated data 
 
Figure 7.8 Depth dose data behind various air gaps, for 2.0 cm water equivalent 
material before the air gap, experimentally determined (a) and Eclipse™ 
calculated (b) results.  The uncertainty for the measured dose is estimated to be 
±2% and for the calculated dose ±2.5%. 
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Depth Dose behind Air Gap
3.0 cm Water Equivalent Slabs before Air Gap
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(a) Experimentally determined data 
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(b) Eclipse™ calculated data 
 
Figure 7.9 Depth dose data behind various air gaps, for 3.0 cm water equivalent 
material before the air gap, experimentally determined (a) and Eclipse™ 
calculated (b) results.  The uncertainty for the measured dose is estimated to be 
±2% and for the calculated dose ±2.5%. 
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Depth Dose behind Air Gap
4.0 cm Water Equivalent Slabs before Air Gap
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(a) Experimentally determined data 
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(b) Eclipse™ calculated data 
 
Figure 7.10 Depth dose data behind various air gaps, for 4.0 cm water equivalent 
material before the air gap, experimentally determined (a) and Eclipse™ 
calculated (b) results.  The uncertainty for the measured dose is estimated to be 
±2% and for the calculated dose ±2.5%. 
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7.4 Results of Transmission Measurements 
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Figure 7.11 Transmission through water equivalent RW3 slabs for a 6 MV photon 
beam, 5 x 4 cm2 field size defined at the isocentre. 
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Transmission Through Water Equivalent Slabs
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Figure 7.12 Transmission through water equivalent RW3 slabs for a 6 MV photon 
beam, 10 x 10 cm2 field size defined at the isocentre. 
  
Page 167 of 169 
7.5 Results of Air Gap Scatter Analysis 
Dose from Scatter created by Water Equivalent Slabs
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Figure 7.13 The dose from scattered radiation created by 0.2 cm of water 
equivalent material before an air gap as a function of depth beyond the air gap 
for various thickness air gaps. The uncertainty in the dose calculation is 
estimated to be ±2.5%. 
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Figure 7.14 The dose from scattered radiation created by 0.5 cm of water 
equivalent material before an air gap as a function of depth beyond the air gap 
for various thickness air gaps. The uncertainty in the dose calculation is 
estimated to be ±2.5%. 
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Figure 7.15 The dose from scattered radiation created by 1.0 cm of water 
equivalent material before an air gap as a function of depth beyond the air gap 
for various thickness air gaps. The uncertainty in the dose calculation is 
estimated to be ±2.5%. 
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Figure 7.16 The dose from scattered radiation created by 2.0 cm of water 
equivalent material before an air gap as a function of depth beyond the air gap 
for various thickness air gaps. The uncertainty in the dose calculation is 
estimated to be ±2.5%. 
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Figure 7.17 The dose from scattered radiation created by 3.0 cm of water 
equivalent material before an air gap as a function of depth beyond the air gap 
for various thickness air gaps. The uncertainty in the dose calculation is 
estimated to be ±2.5%. 
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Figure 7.18 The dose from scattered radiation created by 4.0 cm of water 
equivalent material before an air gap as a function of depth beyond the air gap 
for various thickness air gaps. The uncertainty in the dose calculation is 
estimated to be ±2.5%. 
 
